 
 
 Protocol I 3Y-MC-JPBA(j) 
 
 
Phase 1 Study of a CDK4/6 Dual Inhibitor in Patients with  Advanced Cancer   
 
 NCT0 1394016 
 
Approval Date: 26- Feb-2021 
 
 
  
 
 
I3Y-MC-JPBA (j)Phase 1 Oncology Protocol Amendment Page 1
LY28352191.Protocol I3Y -MC-JPBA (j)
Phase 1 Study  of a CDK4/6 Dual Inhibitor in Patients with 
Advanced Cancer
Confidential Information
The information contained in this protocol is confidential and is intended for the use of 
clinical investigators.  It is the property of Eli Lilly and Company or its subsidiaries and 
should not be copied by or distributed to persons not involved in the cli nical investigation of 
CDK4/6 Inhibitor (LY2835219), unless such persons are bound by a confidentiality 
agreement with Eli Lilly and Company or its subsidiaries.
CDK4/6 Inhibitor (LY2835219)
This Phase 1 study is a single -arm,dose -escalation trial of a CDK4/6 dual inhibitor in 
patients with advanced cancer.
Eli Lilly and Company
Indianapolis, Indiana USA 46285
Protocol Approved by Lilly:   10September 2009
Amendm ent (a) Approved by Lilly:  16October 2009
Amendm ent (b) Approved by Lilly:  10 September 201 0
Amendm ent (c ) Approved by Lilly:  18 October 2010
Amendm ent (d) Approved by Lilly:  0 2 December 2011
Amendm ent (e) Approved by Lilly:  28 March 2012
Amendm ent (f) Approved by Lilly:  14 December 2012
Amendm ent (g) approv edby Lilly :  29August 2013
Amendm ent (h) approved by Lilly: 19 August 2019
Amendm ent (i)approved by Lilly:  07February 2020
Amendm ent (j) Electronically Signed and Approved by Lilly on date provided below.
Approval Date: 26-Feb-2021 GMT
I3Y-MC-JPBA (j)Phase 1 Oncology Protocol Amendment Page 2
LY28352192.Table of Contents
Section Page
1. Protocol  I3Y-MC-JPBA(j) Phase 1 Study  of a CDK4/6 Dual 
Inhibitor in Pat ients with Advanced Cancer ......................................................................... 1
2. Table of Contents ................................................................................................................ 2
3. Abbreviat ions and Definit ions............................................................................................. 8
4. Introduction ...................................................................................................................... 13
4.1. Rationale and Justificat ion for the Study ...................................................................... 13
4.2. Rationale for Amendment (h) ....................................................................................... 14
4.3. Rationale for Amendment (i) ........................................................................................ 14
4.4. Rationale for Amendment (j) ........................................................................................ 14
4.5. Object ives.................................................................................................................... 15
4.5.1. Primary Object ive................................................................................................ 15
4.5.2. Secondary  Object ive(s) ........................................................................................ 15
4.6. General Introduction to LY2835219 ............................................................................. 15
4.6.1. Mechanism of Act ion and In Vitro/In Vivo Activit y............................................. 15
4.6.2. Biomarkers ........................................................................................................... 16
4.6.3. Nonclinical Pharmacokinetics .............................................................................. 16
4.6.4. Nonclinical Pharmacokinetic/Pharmacodynamic Modeling .................................. 17
4.6.5. Nonclinical Toxico logy........................................................................................ 18
4.7. Rationale for Sel ection of Dose and Dose Range .......................................................... 20
5. Invest igational Pl an........................................................................................................... 23
5.1. Study Popul ation.......................................................................................................... 23
5.1.1. Inclusio n Cri teria.................................................................................................23
5.1.2. Exclusio n Cri teria................................................................................................ 24
5.2. Summary  of Study  Design ............................................................................................ 25
5.3. Discontinuati ons .......................................................................................................... 27
5.3.1. Discontinuati on of  Patients................................................................................... 27
5.3.2. Discontinuati on of  Study  Sites............................................................................. 28
5.3.3. Discontinuati on of  the Study ................................................................................ 28
6. Treatment .......................................................................................................................... 29
6.1. Materi als and Supplies .................................................................................................29
6.2. Treatments Administered ............................................................................................. 29
6.2.1. Dosing Schedule .................................................................................................. 29
6.2.2. Dose -Escal ation Phase ......................................................................................... 30
6.2.2.1. Dose -Limit ing Toxicit y Determination and Maximum 
Tolerated Dose Definit ion............................................................................... 32
I3Y-MC-JPBA (j)Phase 1 Oncology Protocol Amendment Page 3
LY28352196.2.2.2. Biologically Effect ive Dose ............................................................................ 32
6.2.3. Dose Confirmat ion Phase (Parts B, C, D, E, F, and G) ......................................... 32
6.2.4. Dose Adjustments ................................................................................................ 33
6.2.4.1. Dose Adjustments ........................................................................................... 33
6.2.4.2. Dose Delays ................................................................................................... 36
6.3. Method of Assignment to Treatment ............................................................................ 36
6.3.1. Continued Access .................................................................................................36
6.4. Blind ing....................................................................................................................... 37
6.5. Concomitant Therapy ................................................................................................... 37
6.5.1. Supportive Management for Diarrhea ................................................................... 38
6.6. Treatment Compliance .................................................................................................39
7. Safety, Pharm acokinetic, Pharm acodynamic, and Efficacy Data 
Collect ion......................................................................................................................... 40
7.1. Safety Evaluat ions........................................................................................................ 40
7.1.1. Safety Data Collection and Review ...................................................................... 40
7.1.2. Adverse Events .................................................................................................... 41
7.1.2.1. Serious Adverse Events .................................................................................. 43
7.1.2.2. Adverse Event and Serious Adverse Event Reporting ..................................... 44
7.1.2.2.1. Prior to Administrati on of  Study  Drug ...................................................... 44
7.1.2.2.2. On Study  Drug .......................................................................................... 44
7.1.2.2.3. Follow-Up Vi sit........................................................................................ 44
7.1.2.2.4. Summary  of Adverse Event/Serious Adverse Event 
Reporting Guidelines ................................................................................ 45
7.1.3. Safety Moni toring ................................................................................................ 45
7.1.3.1. Hepati c Moni toring........................................................................................ 45
7.1.3.2. Renal Funct ion............................................................................................... 46
7.1.3.3. Venous Thromboembo lic Events .................................................................... 47
7.1.3.4. Intersti tial Lung Disease/Pneumo nitis............................................................. 47
7.1.4. Com plaint Handling ............................................................................................. 47
7.2. Sample Collect ion and Test ing..................................................................................... 48
7.2.1. Pharmacokinet ic Evaluat ions................................................................................ 48
7.2.2. Pharmacodynamic Evaluat ions............................................................................. 49
7.2.3. Samples for Standard Laboratory  Testing ............................................................. 50
CCI
I3Y-MC-JPBA (j)Phase 1 Oncology Protocol Amendment Page 4
LY28352197.3. Efficacy Evaluations .................................................................................................... 51
7.4. Procedure/Sampling Co mpliance .................................................................................. 52
8. Data Management Methods ............................................................................................... 53
8.1. Data Qualit y Assurance ................................................................................................ 53
8.2. Data Capture Systems .................................................................................................. 53
8.2.1. C ase Report Form ................................................................................................ 53
8.2.2. Ancillary  Data ...................................................................................................... 54
9. Data Analyses ................................................................................................................... 55
9.1. General Con siderati ons ................................................................................................ 55
9.1.1. Determinat ion of Sample Size (Parts B, C, D, E, F, and G) ................................... 55
9.1.2. Patient Disposi tion............................................................................................... 56
9.1.3. Patient Characteri stics.......................................................................................... 56
9.1.4. Safety Analyses .................................................................................................... 56
9.1.5. Pharmacokinet ic Analyses .................................................................................... 56
9.1.6. Pharmacodynamic Analyses ................................................................................. 57
9.1.7. Pharmacokinet ic/Pharmacodynamic Analyses ...................................................... 57
9.2. Efficacy........................................................................................................................ 58
9.3. Interim Analyses .......................................................................................................... 58
9.3.1. Analysis by Cohort during Dose Escalat ion (Part A) ............................................ 58
9.3.2. Interim Analyses .................................................................................................. 58
10. Inform ed Consent, Ethi cal Review, and Regulatory Considerat ions.................................. 59
10.1. Inform ed Consent ......................................................................................................... 59
10.2. Ethical Review ............................................................................................................. 59
10.3. Regulatory  Considerat ions........................................................................................... 59
10.3.1. Invest igator Informat ion....................................................................................... 60
10.3.2. Protocol  Signatures .............................................................................................. 60
10.3.3. Final Report Signature ......................................................................................... 60
11. References ........................................................................................................................ 61
CCI
I3Y-MC-JPBA (j)Phase 1 Oncology Protocol Amendment Page 5
LY2835219List of Tables
Table Page
Table JPBA.4.1. Overview of Bio marker Strategy .................................................................... 16
Table JPBA.4.2. Exposure Multiples for Oral Administration of LY2835219 Based on 
Administered Dose and Predicted Exposure ................................................... 20
Table JPBA.4.3. Predi cted Steady -State Pl asma Exposure Levels of LY2835219 in 
Hum ans Based on Daily Dosage Level .......................................................... 22
Table JPBA.6.1. Dose -Escal ation Scheme for Study I3Y-MC-JPBA ........................................ 31
Table JPBA.6.2. Toxicit y Dose Adjustments and Delays o f LY2835219 .................................. 33
Table JPBA.6.3. Dose Adjustments of LY2835219 for Study  I3Y-MC-JPBA .......................... 35
Table JPBA.7.1. Adverse Event and Serious Adverse Reporting Guidelines for Study  
I3Y-MC-JPBA .............................................................................................. 45
Table JPBA.9.1. Power Cal culat ion for Study I3Y-MC-JPBA .................................................. 56
I3Y-MC-JPBA (j)Phase 1 Oncology Protocol Amendment Page 6
LY2835219List of Figures
Figure Page
Figure JPBA.5.1. Study  design for I3Y -MC-JPBA. ................................................................... 26
I3Y-MC-JPBA (j)Phase 1 Oncology Protocol Amendment Page 7
LY2835219List of Attachments
Attachment Page
Attachm ent 1. Protocol  JPBA
Study  Schedule .............................................................................................. 63
Attachm ent 2. Protocol  JPBA
Clinical Laboratory  Tests ............................................................................... 68
Attachm ent 3. Protocol  JPBA
Reco mmended Hepat ic Monito ring Tests for Treatment Emergent 
Abnorm ality.................................................................................................. 69
Attachm ent 4. Protocol  JPBA
Pharmacokinet ic and Pharmacodynamic Sampling Schedule ......................... 70
Attachm ent 5. Protocol  JPBA
Reco mmendat ions for Reporti ng Seri ousAdverse Events .............................. 72
Attachm ent 6. Protocol  JPBA
ECOG Performance Status ............................................................................. 74
Attachm ent 7. Protocol  JPBA
Staging and Grading of Acute Graft -versus -Host Disease .............................. 75
Attachm ent 8. Protocol  JPBA
Inducers and Strong Inhibitors of CYP3A ...................................................... 77
Attachm ent 9. Protocol  JPBA
Protocol  Amendment I3Y -MC-JPBA(j) Summary 
Phase 1 Study  of a CDK4/6 Dual Inhibitor in Patients with Advanced 
Cancer ........................................................................................................... 78
I3Y-MC-JPBA (j)Phase 1 Oncology Protocol Amendment Page 8
LY28352193.Abbreviations and Definitions
Term Definition
adverse event ( AE)Any untoward medical occurrence in a patient or clinical investigation subject administered 
a pharmaceutical product and which does not necessarily have a causal relationship with 
this treatment.  An adverse event (AE) can therefore be any unfavorable and unintended 
sign (including an abnormal laboratory finding), symptom, or disease temporally associated 
with the use of medicinal (investigational) product, whether or not related to the medicinal 
(investigational) product.
ALT Alanine aminotransfer ase
ANC Absolute neutrophil count
ASCO American Society for Clinical Oncology
AST Aspartate aminotransfer ase
Assent Agreement from a child or other individual who is not legally capable of providing 
consent, but who can understand the circumstances and risks involved in participating in a 
study (required by some Institutional Review Boards [IRBs]). 
AUC Area under the concentration -time curve
Audit A systematic and independent examination of the trial -related activities and documents to 
determine whether the evaluated trial -related activities were conducted, and the data were 
recorded, analyzed, and accurately reported according to the protocol, applicable standard 
operating procedures (SOPs), good clinical practice (GCP), and the applicable regulatory 
requirement(s).
BED Biologically efficacious dose
Blinding/Masking A procedure in which one or more parties to the trial are kept unaware of the treatment 
assignment(s).  Single -blinding usually refers to the patient(s) being unaware, and double -
blinding usually refers to the patient(s), investigator(s), monitor(s), and in some cases 
select sponsor personnel, being una ware of the treatment assignment(s).
Cmax Maxim alconcentration
CDKI Cyclin-dependent kinase inhibitors
CI Confidence interval
CL Clearance
Com plaint A complaint is any written, electronic, or oral communication that alleges deficiencies 
related to the identity, quality, purity, durability, reliability, safety or effectiveness, or 
performance of a drug or drug delivery system.
Com pliance Adherence to all the trial -related requirements, good clinical practice (GCP) requirements, 
and the applicable re gulatory  requirements.
I3Y-MC-JPBA (j)Phase 1 Oncology Protocol Amendment Page 9
LY2835219Confirmation A process used to confirm that laboratory test results meet the quality requirements defined 
by the laboratory generating the data and that Lilly is confident that results are accurate.  
Confirmation will either occur immediately after initial testing or will require that samples 
be held to be retested at some defined time point, depending on the steps required to obtain 
confirmed results.
consent The act of obtaining informed consent for participation in a clinical study from patients 
deemed eligible or potentially eligible to participate in the clinical study.  Patients entered 
into a study are those who sign the inform edconsent document directly or through their 
legally  acceptable representatives .
CRF Case report form (sometimes referred to as clinical report form):  a printed or electronic 
form for recording study participants’ data during a clinical study, as required by the 
protocol.
CRP Clinical research physician
CSF Cerebrospinal fluid
CT Computerized tomography
CTCAE Common Terminology Criteria for Adverse Events
CYP Cytochrome P450
DLT Dose -limiting toxicity
DNA Deoxyribonucleic acid
ECG Electrocardiogram
ECOG Eastern Cooperative Oncology Group
eCRF Electronic case report form (sometimes referred to as an electronic clinical report form):  
an electronic form for recording study participants’ data during a clinical study, as required 
by the protocol.
End of Study (Trial) End of study (trial) is defined as the date of the last visit or last scheduled procedure at the 
last site shown in the Study Schedule for the last active patient in the study.
enroll Patients who are enrolled in the trial are those who have assigned to a treatment and have 
received at least one dose of study treatment.
enter Patients who are entered in the trial are those who have signed the informed consent 
document directly or through their legally acceptable representatives.
ESA Erythroid -stimulating agents
FFPE Formalin -fixed paraffin -embedded
FNA Fine needle aspi rate
GBM Glioblastoma multiforme, including its variants
I3Y-MC-JPBA (j)Phase 1 Oncology Protocol Amendment Page 10
LY2835219GCP Good Clinical Practice
G-CSF Granulocyte colon y stimulating factors
GFR Glomerular filtration rate
GLP Good Laboratory Practices
GM-CSF Granulocyte -macrophage colony stimulating factors
HBSAg Hepatitis B surface antigen
HR+ Hormone receptor positive
IB Investigator’s Brochure
ICH International Conference on Harmonisation
ICD Informed consent document
ILD Interstitial lung disease
IND Investigational New Drug
Interim Analysis An analy sis of clinical trial data that is conducted before the final reporting database is 
autho rized for datalock.  In a single arm trial, any aggregate summary is considered an 
interim analysis.
Investigator A person responsible for the conduct of the clinical trial at a trial site.  If a trial is 
conducted by a team of individuals at a trial site, the investigator is the responsible leader 
of the team and may be called the principal investigator.
IRB/ERB Institutio nal review board/ethical review board :  a board or committee (institutional, 
regio nal, or national) composed of medical and nonmedical members whose responsibility 
is to verify that the safety, welfare, and human rights of the patients participating in a 
clinical trial are protected.
IV Intravenous
LC/MS/MS Liquid chromatography/mass spectrometry/mass spectrometry
Legal 
RepresentativeAn individual, judicial, or other body authorized under applicable law to consent on behalf 
of a prospective patient, to the patient's participation in the clinical trial.
MATE multidrug and toxin extrusion protein
Monitor A person responsible for ensuring the investigator site complies with the monitoring plan, 
applicable local SOPs (if any), and global Medical SOPs.  Monitors are trained on the 
investigational product(s), the protocol, informed consent document, any other written 
information provided to subjects, relevant SOPs, International Conference on 
Harmonization Good Clinical Practice guidelines (ICH -GCP), and all applicable laws (e.g., 
privacy  and data protection) and regulations. 
I3Y-MC-JPBA (j)Phase 1 Oncology Protocol Amendment Page 11
LY2835219MRI Magnetic resonance imaging
MTD Maximum tolerated dose
NCI Natio nal Cancer Institute
Patient A subject with a defined disease.
PD Pharmacodynamic 
PK Pharmacokinetic
Q12H Every 12 hours
Q24H Every 24 hours
Rb retinoblastoma
RECIST Response Evaluation Criteria in Solid Tumors
SAE Serious adverse event
screen The act of determining if an individual meets minimum requirements for participation in a 
clinical study.
Sponsor The party who takes responsibility for the initiation, management and/or financing of a 
clinical trial.
Study Entry Terms Screen 
The act of determining if an individual meets minimum requirements to become part of a 
pool of potential candidates for participation in a clinical trial.  In this study, screening
involves invasive or diagnostic procedures and/or tests (for example, x -rays, blood draws).  
For this type of screening, informed consent for these screening procedures and/or tests 
shall be obtained; this consent may be separate from obtaining consent fo r the study .
Enter/Consent 
The act of obtaining informed consent for participation in a clinical trial from patients 
deemed eligible or potentially eligible to participate in the clinical trial.  Patients entered 
into a trial are those who sign the inform ed consent document directly or through their 
legally  acceptable representatives.
Enroll
The act of assigning a patient to a treatment.  Patients who are enrolled in the trial are those 
who have been assigned to a treatment.
TBL Total bilirubin level
TED70 Threshold effective dose, 70% inhibition
TPO Third party organization
tmax Time of maximum concentration
CCI
I3Y-MC-JPBA (j)Phase 1 Oncology Protocol Amendment Page 12
LY2835219ULN Upper limits of normal
US United States
Vd Volume of distribution
VTE Venous thromboembolic event
I3Y-MC-JPBA (j)Phase 1 Oncology Protocol Amendment Page 13
LY2835219Phase 1 Study  of a CDK4/6 Dual Inhibitor in Patients with 
Advanced Cancer
4.Introduction
4.1. Rationale and Justification for the Study
During the cell cycle, the G1 restrict ion point con trols entry  into S phase and is essent ial for 
maintaining control of cell divisio n (Ortega et al. 2002; She rr 1996) .  The cy clin-dependent 
kinases, CDK4 and CDK6 (hereafter designated CDK4/6), participate in a complex wit h D-type 
cyclins to init iate the transit ion through the G1 restrict ion point.  A broad spectrum of human 
cancers have alterations in the CDK4/6- cyclinD -INK4-Rb pathway through either increased 
CDK4/6 -cyclinD act ivity or mutations that attenuate funct ion of the INK4 or Rb proteins 
(Mal umbres and Barbacid 2001) .  These alterations render cells less dependent on mitogenic 
signaling for proliferatio n, one of the hallmarks of cancer cells.
The CDK4/6 -cyclinD co mplex regulates the G1 restrict ion point through phosphorylat ion of the 
retinoblastoma (Rb) tumor suppressor protein.  Alterations in this pathway occur frequent ly in a 
broad spectrum of human c ancers and invo lve 1) loss of cyclin -dependent kinase inhibitors 
(CDKI) by mutation or epigenet ic silencing, 2) mutation/overexpressio n of either CDK4/6 or 
cyclin D, or 3) inact ivation of Rb.  With the possible except ion of those tumors with complete 
inact ivation of Rb, which funct ions downstream  of the CDK4/6- cyclinD co mplex, all these 
cancers are potentially  sensi tive to pharm acologic inhibi tion of  CDK4/6.  From a therapeutic 
standpoint, the goal of inhibit ing CDK4/6 with a small mo lecule inhibitor is to prevent cell cycle 
progression through the G1 restrict ion point, thus arresting tumor growth.
LY2835219* represents a select ive and potent small mo lecule CDK4/6 dual inhibitor with broad 
antitumor activit y in preclinical pharmaco logy models, favorable phys ical and pharmacokinetic
(PK) properties, and an acceptable toxi city profile in nonclinical species .  
This compound 
demonstrates si gnificant inhibit ion of tum or growth in 4 human xenograft models:  1) colorectal 
cancer, 2) glioblastoma mult iforme, 3) acute myeloid leukemia, and 4) non –small  cell lung 
cancer .  Alt hough characterized by a different constellat ion of geno mic mutations, each of these 
4 human xenografts has an intact, funct ional Rb protein .  
Xenograft growth inhibit ion is 
generally dose dependent from 25to 100 m g/kg following daily oral administration for 21 day s.
LY2835219 distributes extensively  to the brain (refer to Secti on 4.6.3 and I nvest igator’s 
Brochure [IB]) and therefore provides a unique opportunit y to treat human cancers that have 
metastasized to the brain.  Current ly, these pat ients have short survival and no treatment options 
upon relapse in the brain after receiving radiotherapy .  As a result of its brain exposure, treatment 
with this com pound in a rat orth otopi c brain tum or model produces statistically  significant and 
dose-dependent improvement in survival .
Study  I3Y-MC-JPBA ( Study  JPBA) i s a Phase 1 trial designed to evaluat e the safet y and 
tolerabilit y of LY2835219 in humans .  
The sponsor, monitor, and invest igators will perform this 
I3Y-MC-JPBA (j)Phase 1 Oncology Protocol Amendment Page 14
LY2835219study  in compliance wi th the protocol , GCP and ICH gui delines, and applicable regulatory  
requi rements.
*Formally, LY2835219 refers to the free base whereas LSN2813542 refers to LY2835219 
mesylate; however, LY2835219 has been used for uniformit y throughout thi s protocol , except 
when important for experimental clarit y.
4.2. Rationale for Amendment (h)
Study  JPBA protocol  was amended to update the safet y language regarding hepat ic monitoring, 
assessment of renal funct ion, venous thromboembolic events (VTEs) , and interstit ial lung 
disease (ILD)/pneum onitisto align wit h updated guidance for LY2835219 .  Table JPBA. 6.2was 
added to clarify dose-modificat ionand dose-delay criteria .Section 6.3.1 was added and the 
Study  Schedule (Attachment 1 )wasupdated to incorporate a continued acc ess peri od to all ow 
patients experiencing clinical benefit the option to continue study  therapy  until  1of the cri teria 
for discont inuat ion is met.  The list of Inducers and Strong Inhibitors of cytochrom e P450 (CYP) 
3A (Attachment 8)and Concomitant Therapy (Section 6.5) were also modified to refl ect updated
guidance.
Minor ty pographical and form atting edi ts were made throughout the document for clarit y and 
consistency.
4.3. Rationale for Amendment (i )
Study  JPB Aprotocol  was amended to update safety language regarding ILD/pneum onitis.
Changes to the dose adjust ments and delays in Table JPBA. 6.2were done to specify dose 
modificati ons in response to ILD/pneumo nitisevents . These updates are in alignment with 
changes made in the development core safet y informat ion of the IB.
The protocol was updated to bring references to LY2835219 into alignment with the sponsor’s 
standard language.
Minor ty pographical and form atting edi ts were made throughout the document for clarit y and 
consistency.
4.4. Rationale for Amendment (j)
This amendment to the Study
 JPBA protoco l updates the dose adjust ment guidance related to 
nonhematologic toxicit yandALT /AST increased to ensure alignment with the current IB. 
Specifically , protocol  updates were m ade to the dose adjustment Table JPBA. 6.2. Addit ionally , 
the Concomitant Therapy  (Secti on 6.5) informat ion was updated for CYP3A modulators and 
transporter substrates. Thesafet y monitoring language inHepat ic Moni toring (Secti on 7.1.3.1 )
andVenous Thromboembo lic Events (Secti on 7.1.3.3 )was updated to align with current 
guidance and the IB, respectively. Finally, Secti on 7.1.3.4 was edited slight ly for clarityto 
include specific ILD/pneumo nitis CTCAE grades requiring LY2835219 discont inuation .
Minor ty pographical and form atting edi ts were made throughout the document for clarit y and 
consistency.
I3Y-MC-JPBA (j)Phase 1 Oncology Protocol Amendment Page 15
LY28352194.5. Objectives
4.5.1. Primary Objective
The primary  object ive of this study  is to eval uate the safet y and tol erabili ty of LY2835219 when 
administered orally to patients with advanced cancer.
4.5.2. Secondary Objective(s)
The secondary  objectives of this study  are to:
Determine the pharmacokinet ics (PK) of LY 2835219
Evaluate pharmacodynamic (PD) and predict ive biom arkers
Docum ent the anti tumor activit y ofLY2835219
Establish a recommended dose range for Phase 2 studies.
4.6. General Introduct ion to LY2835219
Detailed informat ion about LY 2835219 is provided in the IB.  This sect ion provi des a summary  
of the inform ation most rel evant for thi s initial Phase 1 study .
4.6.1. Mechanism of Action and In Vitro/In Vivo Activity
LY2835219 represents a novel cl ass of potent ATP compet itive and reversible CDK4/6 kinase 
inhibitor (IC50 for CDK4 = 0.00196 M and IC50 for CDK6 = 0.0099 M).  This mo lecule 
displays a high level o f select ivity over other related cy clin-dependent kinases at the enzyme and 
cellular leve l; for example, LY2835219 is approximately 3 orders of magnitude more select ive 
for CDK4 co mpared to CDK1.  In colo -205 cells, the co mpound induces potent cellular 
inhibit ion of Rb phosphorylat ion (pSer780, IC50 = 0.121 M).  Other data has demonstrated th at 
LY2835219 inhibits CDK4/6 to induce G1 arrest specifically in Rb+ tumors and is selective for 
G1 arrest at concentrations as high as 2.5 to 6 M.
Thisphenoty pic select ivity is also demonstrated in vivo , where LSN2813542 (that is, 
LY2835219 mesylate) suppresses Rb phosphorylatio n and induces a G1 arrest as indicated by 
inhibit ion of toposi omerase IIalpha and phospho -histone H3 (topo IIand pHH3 markers 
respectively ,for cells in S phase and M phase), in a concerted fashio n only consistent with arrest 
at the G1 restriction po int in vivo .  Addit ionally, LSN2813542 showed excellent, sustained PD
response in a mouse colo-205 xenograft model (in vivo pRb inhibit ion ≥50% fro m 1to 36 hours 
post oral  dose of 50 m g/kg and potent suppression of topo IIand pHH3 at 24 h ours post oral 
dose of the same 50 -mg/kg dose) .  Dose response TED 70(thresho ld effect ive dose for 70% 
inhibit ion) values for pRb and topoIIinhibit ion (24 hours post oral dose time po int) were 14.1 
and 14.3 m g/kg, respectively .  This prol onged, r obust target inhibit ion and G1 arrest has resulted 
in the dem onstrati on of  statistically significant, dose-dependent ant itumor activit ies (measured 
by tum or vol ume reduct ion) of LSN2813542 in 4 human subcutaneous xenograft models:  colo -
205 col orectal , H46 0 lung, U87 MG glioblastoma mult iforme and MV4- 11 acute myelo id 
I3Y-MC-JPBA (j)Phase 1 Oncology Protocol Amendment Page 16
LY2835219leukemia.  For example, LSN2813542 can achieve statist ically significant tumor growth
inhibit ionwhen dosed orally at 25, 50 and 100 mg/kg for 21 day sin the colo-205 xenograft 
model.  Consistent with the mechanism o f action of  LSN2813542, the ant itumor activit y in 
colo-205 was associated with a sustained inhibit ion of pRb, topoII and pHH3 (30% to 50% 
inhibit ion of each m arker on day s 14 and 21 of dosing at 100 mg/kg).
As a result of it sbrain exposure, treatment with this com pound produces a stati stically 
significant and dose dependent improvement in survival in a rat orthotopic brain tumor model .  
Median survival was improved 8 and 12 days compared to vehicle following daily  oral treatment
at40 mg/kg and 80 mg/kg for 21days, respectively .
4.6.2. Biomarkers
Biomarkers will be used for 2 key  purposes:  1) to assess PDresponse to LY2835219 in both 
surrogate ti ssues and tumors and 2) to explore the relat ionship between predict ive bio markers 
(such as tumor Rb status )and antineoplast ic act ivity.  
Table JPBA. 4.1provi des an overview of 
the bio marker strategy  for thi s study .  PD bi omarkers will  be measured in proliferat ing cell 
popul ations before and after administration of LY2835219 and will include both pRb (with total 
Rb as a control) and topoiso merase II (topoII).  PD bio markers will be measured in hair 
follicles and skin throughout the study  (Parts A, B, C, D, E, F,and G ) and, whenever clinically 
feasible, in tumors during dose confirmat ion (Parts B, C, D, E, F,and G ).  Potential predictive 
biomarkers will be measured throughout the study  in archived tum or tissue (for exam ple, f rom 
prior biopsy ) during dose confirmat ion (Parts B, C, D, E, F,and G ).
Table JPBA .4
.1. Overview of Biomarker Strategy
Tissue Biomarke rs Purpose
Hair follicles pRb, total Rb, topoII  PD
Skin pRb, total Rb, topoII  PD
Tumo rs (pre -and post -
LY2835219)pRb, total Rb, topoII  PD / Predictive
Archived tumors pRb, total Rb Predictive
Abbreviations :  PD = pharmacodynamic; pRb = phosphorylated retinoblastoma protein ; topoII = topoisomerase 
IIprotein ; total Rb = total retinoblastoma protein .
4.6.3. Nonclinical Pharmacokinetics
Preliminary PKparameters of LY2835219 were estimated in mouse, rat, and dog fo llowing a 
single intravenous (I V) or oral dose of LY2835219 as the mesylate salt.  When administered 
orally , the absorpti on was relat ively slow in rat ( time of maximum concentration [ Tmax] 3 hours) 
and dog (T max9 hours) but rapid in mouse (T max0.5 hour) at a comparable dose (1 or 3 m g
/kg).  
Overall, the oral bioavailabilit y was m oderate to high in these species.  Following IV 
administration, plasma clearance was moderate and volume o f distribut ion was high in all 
3species with eliminat ion half-lives ranging fro m approximately  6 to 17 hours.  After oral 
dosing, LY2835219 was distributed well into brain tissues in rat and to a relatively lesser extent 
in mouse.
I3Y-MC-JPBA (j)Phase 1 Oncology Protocol Amendment Page 17
LY2835219The pl asma toxi cokinet ics of LY2835219 were evaluated in rats and dogs following daily oral 
doses for 28 days.  In rats, exposur es increased slight ly less than proportionally to the increase in 
dose from 10 to 50 mg/kg/day.  A slight accumulatio n (approximately  up to 2 -fold) was observed 
with repeated daily dosing of LY2835219 for 14 days; however, exposure on Day  28 was 
generally similar to that observed on Day  14, indicating that steady  state might have been 
achieved between Day  14 and Day  28.  In dogs, exposures generally increased proportionally  to 
the increase in dose fro m 1 to 10 mg/kg/day.  A slight accumulat ion (approximatel y 1.5-to 
3-fold) of LY2835219 was observed wit h repeated daily dosing for 12 or 14 day s.  Again, 
exposure on Day  28 was generally  similar to that observed on Day  14, suggest ing that steady  
state might have been achieved between Day  14 and Day  28.  In both species, there were no 
notabl e gender differences in exposure.
4.6.4. Nonclinical Pharmacokinetic/Pharmacodynamic Modeling
The primary  object ive of PK/PDmodeling in preparation for the Phase 1 study  was to estimate a 
pharmaco logically effect ive and safe dose ra nge in huma ns, based on preclinical data.
The nonclinical PK/PD analysis was conducted using data generated using a co lo-205 xenograft
model devel oped in the mouse.
A PK/PD m odel was developed to relate the predicted plasma concentrations to the observed 
level of in vivo CDK4/6 inhibit ionin the colo -205 xenograft tumor model (measured by the 
extent of pRb, topoIIα and pHH3 inhibit ion).  A series of transit compartments connected to a 
precursor compartment was used to relate the predicted plasma concentrati ons wi th the observed 
level of these bio markers by means of an indirect response model (Sharma et al . 1998; Sun and 
Jusko 1998; Hazra et al. 2006; Mager and Jusko 2001). In order to establish a connect ion 
between CDK4/6 inhibit ion and in vivo efficacy  (measured by the tum or growth del ay) following 
drug administration, a fully -integrated PK/PD/IVE model was developed by connect ing the 
PK/PD m odel described above to a model describing the kinet ics of tum or growth by  means o f a 
modified Go mpertz model (Simeoni et al . 2004).  Thispreclinical PK/PD mode ling indicated 
that the minimum level of CDK4/6 inhibit ion associ ated wi th in vivo tumor growth delay  after 
repeated administration is 30% to 50% maintained throughout the whole duration of the 
treatment.  Aprojected human PK model,obtained fro m allometri c scaling
,was linked to this 
PK/PD m odel generated from  the mouseefficacy data to simulate the human PD profiles .These 
simulat ions suggest that a minimum daily  dose of 150to 300 mg is expected to produce the 
minimum level of CDK4/6 inhibit ionthat has been associ ated wi th tumor growth del ay in the 
preclinical studies.
Finally , the range of area under the concentration -time curve ( AUC )levels requi red to produce 
in vivo efficacy in colo-205 tumor -bearing mice was approximately 3600 to 9500 ng hr/mL.  
Simulations using the projected human PK model obtained by  allometric scaling were used to 
determine the dose range in human that should produce a similar exposure range
. The prediction 
intervals obt ained from t hese simulat ions suggest that such exposures should be reached at a 
daily  dose level  of approximately 300 to 700 m g.
I3Y-MC-JPBA (j)Phase 1 Oncology Protocol Amendment Page 18
LY28352194.6.5. Nonclinical Toxicology
To support human clinical studies, the toxicit y profile of LY2835219 has been effect ively 
characterized in rat and dog through a package of repeat -dose toxico logy, safety  pharmacol ogy, 
and genet ic toxico logy studi es.  These studies demonstrate an acceptable safet y profile wi th 
toxicities that are generally  considered to be monit orabl e and reversible.
For Study  JPBA, a clinical starting dose of 50 mg adminis tered daily  for 28 day s on a 28 -day 
cycle was selected based on the highest doses of LY2835219 in nonclinical toxicology  studi es 
that did not produce any  toxicities considered to be irreversible and/or n onmoni torabl e.  Based 
on the effects of LY2835219 observed in rats and dogs, the dose -limit ing toxicit y (DLT) in 
humans i s expected to be reversible myelosuppressio n and/or gastrointestinal toxicit y.  Mortalit y 
associ ated wi th administrati on of  LY2835219 w as limi ted to the hi ghest doses invest igated of 
50mg/kg (300 mg/m 2) in rats and 10 m g/kg (200 mg/m 2) in dogs.  In rats, mortalit y occurred in 
2 of 30 rats given 50 mg/kg and was associated with clinical signs of dehydration, reduced food 
consumption, body weight l oss, decreased act ivity, and soft stools and/or reduced feces.  In dogs, 
declining clinical condit ion of animals given 10 mg/kg started on Day  9, leading to euthanasia of 
2 dogs on Days 12 and 15 and early termination o f the dose group on Day  18. The dogs 
exhibited clinical signs including but not limited to :  decreased activit y and food consumpt ion, 
dehydrat ion, thinness, hypothermia, red and/or liquid and/or soft feces, and paleness.  These 
animals also exhibited marked pancytopenia characterize d by decreases in reticulocytes, 
leukocy tes(neutrophil s, monocy tes, and lymphocyte s),and platelets.  The cause of the mortalit y 
in dogs was attributed to gastrointestinal lesio ns in conj unction with marked myel osuppressi on.
The nonclinical toxico logy studies consisted of 28 -day repeat -dose studies in rats at doses of 10, 
30, and 50 mg/kg/day (60, 180, and 300 m g/m2, respect ively) and in dogs at doses of 1, 3, and 
10mg/kg /day (20, 60, and 200 mg/m 2, respect ively).  The dosing schedule was designed to 
reflect the m ost dose -intense regimen in the Phase 1 clinical dosing study.  Dose-responsive 
hematotoxicit y (as indicated by  cytopenias and bone marrow hy pocellularit y)and 
gastrointestinal injury  were the m ost prominent adverse effects observed in both rats a nd dogs.  
Changes in hematology  parameters exhibited partial or complete reversibilit y within the 28 -day 
recovery  period in both speci es.
Besides the clinical signs and hematologic effects described above, morpho logic changes were 
observed in several t issues.  Im portant findings that were considered adverse consisted of bone 
marrow hy pocellularit y in rat and dog; intestinal crypt hy perpl asia and villous atrophy  in rat and 
dog, associated with minimal neutrophilic inflammation in rat; lympho id deplet ion in the thymic 
cortexand lymph nodes in rat and dog; macrophage accumulat ion in the lungs and 
bronchoalveo lar inflammat ion in rat; and changes in the male reproductive tract (germ  cell 
degeneration and depletion; atrophy  of the seminal vesicle, seminiferous tu bule epithelium, and 
prostate) in rat and dog.  These changes demo nstrated complete or partial reversibilit y within the 
28-day recovery  period.
Other morpho logic changes seen in either rat or dog were generally considered minor and not 
considered to be tox icologically  important.  In rats, microscopic changes at higher doses 
I3Y-MC-JPBA (j)Phase 1 Oncology Protocol Amendment Page 19
LY2835219included tubular vacuo lar degenerat ion inthe kidneys wi thout evidence of renal  functional 
impairment ; diffuse vacuolation o f acinar cells in the pancreas wi thout evidence of cellular 
degenerati on or functional impairment ; macrophage vacuo lation in the spleen; myo fiber 
degeneration/necrosis; andhypercellularit y of the thymic medulla .  In dogs, cytoplasmic 
eosinophilia/decreased vacuo lationandmononuclear cell infiltrat ion were seen in t he adrenal 
gland, which were not accom panied by  a notabl e change in cell size or eviden ce of degenerat ion 
or necrosi s.
LY2835219 was also invest igated in a standard battery of safet y pharmaco logy and genet ic 
toxicologystudi es.  No adverse findings associa ted wi th respiratory  and central  nervous system  
funct ion were observed in rats.  LY2835219 was negative in a standard battery  of genotoxi city 
tests (Ames, chrom osom al aberrati on, and rat micronucleus) and is thus not considered to be a 
genotoxi cant.
In the cardi ovascular safet y pharm acology study , ventri cular tachy cardi a occurred in 1 of 8 dogs 
given 10 mg/kg, the highest dose administered.  Th isarrhy thmia occurred intermittently between 
22 and 48 hours postdose .  Although parent drug is detectable during this period fo llowing oral  
administration in dogs, occurrence of ventricular tachycardia did not correl ate wi th the m aximum  
plasma l evel of LY2835219.  No blood pressure changes were associated with th isarrhy thmia, 
and n o QTc prol ongat ion was observed in dogs at doses up to 10 mg/kg .  Based upon the 
incidence in only a single animal and the delayed onset, the arrhy thmia was likely caused by 
ventri cular i rritation ori ginat ing from the insert ion site of the left ventricular pressure transducer 
and/or posi tive ECG el ectrode.  However, as ventricular tachycardia was noted only fo llowing 
the high dose, a compound-related effect i s possible.
In conclusio n, results fro m the nonclinical toxicology , safet y pharmaco logy, and genet ic 
toxicology studi es for LY2835219 demonstrate an acceptable safet y profile wit h toxi cities that 
are generally  considered to be m onitorable and reversible.  Based on the repeat -dose toxicit y 
studi es, a starting dose of 50 mg (31 mg/m 2) given daily for28 days was selected for 
Study JPBA .  Table JPBA. 4.2shows the calculated exposure mult iples for doses from 50 m g 
(31mg/m2) to 900 m g (562 mg/m2).
More detailed informat ion about the characteristics of LY2835219 can be found in the IB.
I3Y-MC-JPBA (j)Phase 1 Oncology Protocol Amendment Page 20
LY2835219Table JPBA .4.2. Exposure Multiples for Oral A dministration of LY2835219 Based on 
Administered Dose and Predicted Expo sure
Dose
(mg/kg)Dose
(mg/m2)Dose
MultipleaAUC 0-24 hr
(nghr/mL)Exposure 
Multiple b
Human c
   Starting Dose 0.8 31Rat: 10
Dog: 2450Rat: 52
Dog: 1.8
   Planned
   Highest Dose15 562Rat: 0.5
Dog: 0.17,800Rat: 3
Dog: 0.1
Rat NSTD d 50 300 - 23,800 -
Dog MinTD e 3 60 - 800 -
Abbreviations:  NSTD = highest Not Severely Toxic Dose; MinTD = highest Minimally Toxic Dose ; 
AUC 0-24 hr = area under the concentration versus time curve from time 0 -24 hours.
aDose multiple is the dose in animals /dose in humans based on body surface area (mg/m2).
bExposure multiple is the mean calculated AUC 0-24 hr (males and females) on Day 1 in animals / predicted 
AUC 0-24 hr ,in humans at steady state .  The AUC 0-24 hr on Day 1 in animals are summarized in Sect ion 5.1.3 of 
the Investigator’s Brochure (Tables 5.2 and 5.3).
cAssumes body weight of 60 kg and body surface area of 1.6 m 2.
dNSTD based on 28-day repeat -dose toxicity study in rats (803871) .
eMinTD based on 28-
day repeat -dose toxicity study in dogs (803872) .
4.7. Rationale for Selection of Dose and Dose Range
For the once daily schedule , an initialdose range of 50 to 900 m g of LY2835219 administered 
orally  once daily  for 28 day s was selected based on nonclinica l toxicology and PK/PD data.  For 
dose escalat ion on thi s schedule, there were 9 planned dose levels:  50, 100, 150, 225, 300, 400, 
525, 700, and 900 mg administered orally every  24 hours for 28 day s.
Table JPBA. 4.3summarizes the predi cted m edian steady -state AUC and90% predict ion interval 
for the initially planned dose l evels to be tested in Study  JPBA .  Exposure levels (AUC 0-24 hr ) on 
Day 1 and at st eady state in rats and dogs are summarized in the IB.  Based on a starting dose of 
50 m g given once daily and the exposures on Day 1 at the Not Severely Toxic Dose in rats and 
highest Minimally Toxic Dose in dogs, the median predicted exposure mult iples were 
approximately  52 and 1.8, respectively.  Based on the steady -state exposures observed at these 
doses in rats and dogs, the exposure mult iples predicted for this starting dose of 50 mg were 
approximately  106 and 4.2 ,respectively.
Preclinical efficacy associated with administration of LY2835219 was evaluated by 2endpo ints:  
1) CDK4/6 inhibit ion (measured by  the extent of phosphorylated Rb, topoIIα and pHH3 
inhibit ion) in xenograft tumors implanted in mice; and 2) exposure levels as sociated wi th 
xenograft tumor growth delay in mice.  These efficacy parameters were integrated into a 
nonclinical PK/PD model.
Modeling the level o f CDK4/6 inhibit ion associated with tumor growth delay in mice suggested
that a clinical dose of 150to 300 mg,administered once daily, shoul dproduce exposure levels 
demonstrated to produce the minimum level of CDK4/6 inhibit ion associ ated wi th efficacy  in 
preclinical studies. Based on the steady -state exposures at the Not Severely  Toxic Dose in rats 
I3Y-MC-JPBA (j)Phase 1 Oncology Protocol Amendment Page 21
LY2835219and the highest Mi nimally Toxic Dose in dogs, the median exposure mult iples predicted at 
steady  state for thi s clinical dose range were approximately  18 to 33 and 0.7 to 1.3 respectively .
In addit ion, PK/PD modeling suggested that AUC levels associated with tumor growth delay in 
preclinical in vivo efficacy  studi es (approximately  3600 to 9500 ng hr/mL) should be reached in 
patients wi thin a dose range of 300 to 700 mg administered once daily ( Table JPBA. 4.3).  Based 
on the steady -state exposures observed at the Not Severely  Toxic Dose in rats and the highest 
Minimally Toxic Dose in dogs, the median exposure mult iples predicted at steady  state for thi s 
clinical dose range were approximately  8 to 18 and 0.3 to 0.7, respectively.
During the dose escalat ion phase, preliminary analysis o f PK data fro m the init ial 4 dose levels 
(50, 100, 150, and 225 mg every  24hours) indicated less than dose -proportional increases i n 
exposure.  Based on these results, a twice daily schedule was introduced in Part A wit
h 
LY2835219 administered orally at the fo llowing planned dose levels:  75, 100, 150, 200, 275, 
350, and 450 mg every 12 hours for 28 days.  Im portantly , the fi rst pl anned dose l evel (75 m g 
every 12 hours) corresponded to a daily dose of 150 mg, which was 1 dose l evel l ower than that 
of the highest previously  expl ored dose l evel (225 mg every  24hours).   Forthe twice daily 
schedule, the highest dose of LY2835219 evaluated was275mg every  12 hours .  At this dose 
level , 2of the 3 patients experienced DLT of Grade 3 fat igue.  At the next lower dose level o f 
200 m g every  12 hours, 1 of the 7 pati ents also experi enced DLT of Grade 3 fatigue.  T herefore, 
the maximum t olerated dose ( MTD) was established at 200 m g every 12 hours.
During the tumor -specific expansion phases, patients initially receive dLY2835219 at the MTD
of 200 m g every 12 hours. Apreliminary interim safet y review wit h data from 5 6patients 
indicated t hat 29patients experienced diarrhea possibly related to study drug:  17Grade 1 ( 30%), 
9Grade 2 (16%), 3Grade 3 (5%), none Grade 4 (0%), and none Grade 5(0%) .  Based on the 
frequency  of Grade 1/2 diarrhea and the observat ion of clinical activit y at doses below the MTD , 
the initial starting dose was changed to 150 mg every  12 hours wi th JPBA amendment (f) to gain 
additional PK data and clinical experience around safet y/tolerabili ty.  
Importantly, di arrhea 
experienced by patients is manageable with sta ndard anti -diarrheal agents.  Therefore, early 
treatm ent wi th anti-diarrheal  agents ( e.g., loperamide) is recommended and the init ial starting 
dose will return to the MTD of 200 mg every 12 hours with JPBA amendment (g).
I3Y-MC-JPBA (j)Phase 1 Oncology Protocol Amendment Page 22
LY2835219Table JPBA .4.3. Predicted Steady -State Plasma Exposure Levels of LY2835219 in 
Humans Based on Daily Dosage Level
Daily dose (mg)Predicted AUC 0-24 hr, ss in Humans (ng hr/mL)
Median 90% Prediction Interval
50 450 (200 – 1,000)
100 900 (400 – 1,900)
150 1,450 (550 – 3,000)
225 2,000 (900 – 4,600)
300 2,700 (1,200 – 5,800)
400 3,650 (1,600 – 8,100)
525 4,700 (2,100 – 10,400)
700 6,250 (2,700 – 13,800)
900 7,800 (3,500 – 17,200)
Abbreviation :  AUC 0-24 hr, ss= area under the concentration versus time curve from time 0 -24 hours at steady state.
I3Y-MC-JPBA (j)Phase 1 Oncology Protocol Amendment Page 23
LY28352195.Investigational Plan
5.1. Study Population
5.1.1. Inclusion Criteria
Patients m ay be included in the study  if they  meet all  of the f ollowing cri teria:
[1] For all Parts:  The patient m ust be, in the j udgment of the invest igator, an 
appropriate candidate for experimental therapy , either after available standard 
therapi es have ceased to provide clinical benefit (Parts A, B, C, D, E, and F) 
or in co mbination wit h fulvestrant (Part G only) .
For Dose Escalation (Part A):  The patient must have histological or 
cytological evidence of cancer, either a solid tumor or a lymphoma, which is 
advanced and/or metastatic .
For Dose Confirmat ion (Parts B, C, D, E, F, and G ):  The patient must h ave 
histol ogical or cy tological evidence of one of the following cancers :
Part B:  Non -small cell lung cancer of any subt ypethat is advanced and/or 
metastati c.
Part C:  Glioblastom amultiforme(GBM) that has progressed or recurred 
after radi otherapy  and/o r chemotherapy .
Part D:  Breast cancer that is advanced and/or metastatic.
Part E:  Melano ma that is advanced and/or metastatic.
Part F:  Colorectal  cancer that i s advanced and/or metastatic.
Part G: Breast cancer that is not only  advanced and/or m etastat icbut al so 
horm one receptor posit ive (HR+) .  The pati ent mustbe a postmenopausal 
wom an wi th disease progressi on following anti-estrogen therapy  and m ay be
currently receiving fulvestrant at the time of study entry .
[2] Have the presence o f measurable or non -measurable disease as defined by  the 
Response Evaluat ion Cri teria in Solid Tumors (RECIST 1.1, Eisenhauer et al . 
2009) or the Revised Response Criteria for Malignant Lympho ma (Cheson et 
al. 2007 ),
For Parts Aand G : Have measurable or nonmeasurab le disease.
For Parts B, C, D, E, and F: Have measurable disease .
[3] Are 18 years of age.
[4] Have given written informed consent prior to any  study -specific procedures
I3Y-MC-JPBA (j)Phase 1 Oncology Protocol Amendment Page 24
LY2835219[5] Have adequate organ funct ion including:
Hem atologic:  Absol ute neutrophil count (ANC) 1.5x 10 9/L platelets 
100 x 10 9/L, and hemoglobin 8g/dL.  Pati ents may receive ery throcyte 
transfusio ns to achieve this hemoglobin level at the discret ion of the 
investigator; however, init ial study  drug treatm ent must not begin earlier 
than the day after the ery throcyte transfusio n.
Hepati c:  Bilirubin 1.5 times upper limit s of normal  (ULN) and alanine 
aminotransferase (ALT) 3.0times ULN.
Renal:   Serum  creat inine ULN .
[6] Have a performance status ≤1 for Dose Escalation (Part A) and ≤2 for Dose 
Confirmation (Parts B, C, D, E, F,and G ) on the Eastern Cooperative 
Onco logy Group (ECOG) scale (refer to Attachment 6).
[7] Have discontinued all previous therapies for cancer (including chemotherapy, 
radiotherapy , immunotherapy , and invest igational therapy ) with the excepti on 
of fulvestrant (for Part G only) for at least 21 day s for myel osuppressive 
agents or 14 day s for nonmy elosuppressive agents pri or to receiving study  
drug, and recovered fro m the acute effects of therapy  (treatm ent rel ated 
toxicity resolved to baseline) except for residual alopecia .
[8] Are reliable and willing to make themselves available for the duration of the 
study  and are willing to follow study  procedures.
[9] Males and females with reproductive potential must agree to use medically 
approved contraceptive precautions during the trial and for 3 months 
following the last dose of study  drug.
[10] Females with child bearing potential must have a negative serum pregnancy  
test wi thin 3 days of the first dose of study  drug.
[11] Have an est imated life expectancy o f ≥12 weeks.
[12] Are able to swallow capsules.
5.1.2. Exclusion Criteria
Potenti al study  patients m ay no t be included in the study if any of the fo llowing apply:
[13] Have received treatment with a drug that has not received regulatory  approval  
for any  indicati on wi thin 14 or 21 days of the init ial dose of study  drug for a 
nonmyelosuppressive or myelosuppres sive agent, respect ively.
[14] Have a personal history  of any of the fo llowing condi tions:  presyncope or 
syncope of either unexplained or cardiovascular et iology , ventricular 
arrhy thmia (incl uding but not limited to ventricular tachycardia and 
ventri cular fibrillation), sudden cardiac death, or sudden cardiac arrest.
[15] Exclusio n Cri terion [15
] has been deleted.
I3Y-MC-JPBA (j)Phase 1 Oncology Protocol Amendment Page 25
LY2835219[16] Have serious preexist ing medical condit ions that, in the judgment of the 
investigator, would preclude participat ion in thisstudy  (for exam ple, history  
of major surgi cal resecti on invo lving the stomach or small bowel ).
[17] For Dose Escalation (Part A):  Have CNS m alignancy or m etastasi s.  
Screening of asymptomat ic patients without history o f CNS m etastases is not 
requi redfor enrollment .
ForDose Confirmat ion (Parts B, D, E, F,and G ):  Have CNS metastasi sthat 
is radiographically or clinically unstabl e less than 14 day s prior to receiving 
study drug, regardl ess of whether they  are receiving corticosteroids.
For Dose Confirmat ion (Part C):  Have GBM that is radiographically or 
clinically un stabl e less than 14 days prior to receiving study  drug, regardless 
of whether they  are receiving corticosteroids.
[18] Have anacute leukemia.
[19] Have received an autol ogous or allogeneic stem -cell transplant within 75 days 
of the ini tial dose of study  drug.  In addi tion, reci pients of an allogenic stem -
cell transplant must have discont inued immuno suppressive therapy  at least 
11days before study  drug administrati on wi th nomore than Grade 1 acute 
graft -versus -host disease (refer to Attachment 7for gradin g and staging o f 
graft -versus host disease) on Day -3.
[20] Females who are pregnant or lactating.
[21] Have act ive bacteri al, fungal, and/or known viral infect ion (for exam ple,
human immunodeficiency virus [HIV] antibodies, hepat itis B surface antigen 
[HBSAg], or hepatit is C antibodies) .  
Screening is not required for enrollm ent.
5.2. Summary of Study Design
This study is a mult icenter, nonrando mized, open -label, dose -escalation Phase 1 trial of 
LY2835219 in approximately 300 patients wi th advanced cancer .  During dose escalat ion 
(Part A), 33 patients were treated across 2 schedules.  For the once daily schedule, pati ents 
receive dLY2835219 orally  every 24 hours.  For th e twicedaily schedule, patients receive d
LY2835219 orally  every  12 hours for D ays 1 through 28 of a 28 -day cycle (refe r to 
Figure JPBA. 5.1), with modificat ions during Cycle 1 to enable PK sampling fo llowing a single 
dose and repeated doses.  During dose escalation , cohorts of at least 3 patients were enrolled at 
each of the planned dose l evels.
During dose escalat ion(Part A) , 33 pati ents were treated across 2 schedules.  For the once daily  
schedule, patients were treated at 50, 100, 150, and 225 mg every  24 hours ( Q24H).  For the 
twice daily  schedule, pati ents were treated at 75, 100, 150, 200, and 275 mg every  12 hours 
(Q12H ).  An MTD for the once daily schedule was not reached ,whereas the MTD for the twi ce 
daily  schedule was tentatively established (pending dose confirmat ion) at 200 mg Q12H.  As 
depicted in Figure JPBA. 5.
1, the study  design consists of a dose escalation pha se (Part A) and 
6 tumor
-specific expansion phases (Parts B , C, D, E, F,and G ).  The dose escalat ion phase 
I3Y-MC-JPBA (j)Phase 1 Oncology Protocol Amendment Page 26
LY2835219(Part A), described in Sect ion 6.2.2 , wasguided by safet y assessments fro m Days 1 through 28 
of Cycle 1 for all pat ients in the cohort and also by the emerging PKdata.   Dose escalat ion 
occur reduntil the MTD (defined in Sect ion6.2.2.1 ) was determined for at least 1 schedule.
After the last patient enrolled in the dose escalat ion phase ( Part A )complete s Cycle 1, then the 
6tumor-specific expansio n phase s(Part s
B, C, D, E,F,and G ) maybegin.  In each tumor -
specific expansion phase, at least 15and up to 45 -60 patients will be treated on the twi ce daily  
schedule at a dose no greater than the MTD (200 mg every  12 hours ) with administrati on of  
LY2835219 on Day s 1 through 28 of a 28 -day cycle ,with modificat ions during Cycle 1 to 
enable PK sampling fo llowing a single dose and repeated doses.   Patients enrolled in Part G 
shoul d receive fulvestrant according to the study schedule .
All p atients in the study  receive 2 cycles of LY2835219 unless one or m ore of the criteria for 
discontinuat ion (refer to Section 5.3.1 ) are fulfilled ; the follow-up peri od for pos tstudy 
evaluat ion is 30 ±7 days from the date of the last dose of study  drug received .  A p atient may 
receive more than 2 cy cles of treatment only  if 1) none of the cri teria for discont inuation have 
been fulfilled, and 2) the invest igator, in consultation with the Lilly clinical research physician 
(CRP), determines that the patient is experiencing clinical benefit from treatment .
Refer to Attachment 1 for the detai led study  schedul e.
Abbreviation s:  HR+ = hormone receptor positive ; Q12H = every 12 hours; 
Q24H =every 24 hours .
Figure JPBA .5.1 . Study design for I3Y-MC-JPBA .

I3Y-MC-JPBA (j)Phase 1 Oncology Protocol Amendment Page 27
LY28352195.3. Discontinuations
5.3.1. Discontinuation of Patients
The cri teria for enrollment m ust be fo llowed explici tly.  If a pati ent who does not meet 
enrollment criteria is unintent ionally enrolled, Lilly  or its desi gnee must be contacted.  In these 
rare cases, the invest igator must obtain documented approval fro m Lilly to all ow the pati ent to 
continue in the study .
In addit ion, pati ents will  be discont inued fro m the study  in the fo llowing ci rcumstances:
The invest igator or attending physician decides the patient should be 
withdrawn.  If thi s decisio n is made because of a seri ous adverse event or a 
clinically significant laboratory  value, then appropri ate supportive measures 
are to be taken.  Lilly  or its desi gnee is to be al erted immediately.  (Refer to 
Secti on 7.1).
The patient requests to be wi thdrawn from  the study .
The patient, for any  reason, requi res treatm ent wi th another therapeuti c agent 
that has proven efficacious in the treatment of the study  indicat ion.  In thi s 
case, di scontinuat ion from the study  occurs pri or to introducti on of  the new 
agent.
The invest igator or Lilly, for any ethical, medical, or scient ific reason, while 
considering the rights, safet y, and well -being of the patient(s), stops the s tudy 
or stops the patien t’s parti cipati on in the study .
The patient experiences unacceptable toxicit y, including but not limited to the 
following circumstance (refer to Section 6.2.4.2 ):
The patient does not meet the criteria for recover yfrom toxicity within 
14daysof the l ast day  of the previ ous cycle.
The patient is nonco mpliant with study  procedures and/or treatment .(refer to 
Secti on6.6).
The patient has evidence of progressive disease.
Patients who discont inue the study drug and/or study early will have end -of-study  and f ollow-up 
procedures performed as shown in the Study  Sche dule (Attachment 1 ).
For dose escalat ion (Part A), a ny patient who i s discontinued fro m the study  before receiving at 
least 75% of planned doses of LY2835219 in Cycle 1 will be deemed nonevaluable for 
assessment of thatdose level and may be replaced unless they  experience a DLT before 
withdrawal .  Nonevaluable patients may  be replaced to ensure that no fewer than 3 pati ents 
receive at least 75 % of planned doses of LY2835219 in Cycle 1 at each dose level, unless 
enrollment to that cohort has stopped because more than 1 patient at that dose level has 
experienced a DLT .  Pati ents who com plete Cycle 1 of therapy but are not evaluable for PK may 
be replaced upon consu ltation wi th the invest igator(s) and the Lilly  CRP to ensure adequate PK 
I3Y-MC-JPBA (j)Phase 1 Oncology Protocol Amendment Page 28
LY2835219data collect ion, unless enrollment to that cohort has stopped because more than 1 patient at that 
dose l evel has experienced a DLT .
For Part G , any pat ient who i s discont inued fro m the study  for a reason other than progressive 
disease and before receiving a post -treatm ent radi ological tum or assessment will be deemed 
nonevaluable for assessment of response .  Addit ional pat ients may be enro lled to replace 
nonevaluable pat ients.
5.3.2. Discontin uation of Study Sites
Study  site parti cipat ion may be discont inued if Lilly, t he invest igator, the inst itutional review 
board (IRB) /ethical review board (ERB) or the regul atory  authori tydeems it necessary  for any 
scientific, medical, or ethical reason.
5.3.3. Discontinuation of the Study
The study  will be di scontinued if Lilly, while considering the rights, safet y, and well -being o f the 
patient(s), deems it necessary  for any scient ific, medical, or ethical reason .
I3Y-MC-JPBA (j)Phase 1 Oncology Protocol Amendment Page 29
LY28352196.Treatment
6.1. Materials and Supplies
LY28 35219 will be supplied by the sponsor for oral  administrati on.  LY28 35219 shoul d be 
stored at room temperature according to the label, and not opened, crushed, or disso lved.  
Invest igators should instruct patients to store LY28 35219 in the original package and in a 
location inaccessible to children.  Clinical study materials will be labeled according to US
regul atory  requi rements.
For Part G, patients with HR+ breast cancer should receive fulvestrant as specified in the label . 
Fulvestrant (50 m g/mL) is ava ilable co mmercially, should be stored and administered according 
to the l abel, and will not be supplied.
6.2. Treatments Administered
The invest igator or his/her designee is responsible for:
explaining the correct use of the investigational agent and planned du ration of  
each individual’s treatment to the patient and, if appropriate, to the patient’s 
designated legal representative ,
verifying that instructions are fo llowed properly ,
maintaining accurate records of study  drug di spensati on, destructi on, and 
collect ion, and
returning or destroying all unused m edicat ion to Lilly or its designee at the end of 
the study .
Patients will  be instructed to contact the investigator as soon as possible if they  have a com plaint 
or probl em with the study  drug so that the situati on can be assessed.
6.2.1. Dosing Schedule
For the once daily schedule , pati ents will  cont inue to receive LY2835219 orally every  24hours 
(±3hours) for Day s 1 through 28 of a 28 -day cycle.  For the twice daily  schedule , pati ents will  
receive LY2835219 orally  every 12 hours (±3 hours) for Days 1 through 28of a 28 -day cycle.  
For both schedules, there are modificat ions during Cycle 1 to enable PK sampling fo llowing a 
single dose and repeated doses.
During Cycle 1 on the twice daily  schedule ,the initial dose of study drug will be taken on Day  -3 
to enable PK sampling over 72 hours following a single dose; the remaining 55 doses will be 
taken every  12 hours on Days 1 to 28, with PK sampling on Day  1 and Day  15 and over 24 hours 
following the single dose taken on Day 28.  For Cycl e 1, pati ents shoul d be specifically  
instructed not to take a second dose of study  drug on Day  28; if such a dose is inadvertently 
taken on Day  28, i t const itutes a protocol vio lation.  Patients should not consume food beginning 
1hour bef ore and ending 1 hour after taking study  drug .
During Cycle 2 and bey ondon the twice daily  schedul e,study drug i s taken orally every  
12hours on Day s 1 through 28 of a 28 -day cycle .
I3Y-MC-JPBA (j)Phase 1 Oncology Protocol Amendment Page 30
LY2835219During all cycles, study  drug shoul d be taken at approximately the same time(s)each day .  If a 
patient misses or v omits a dose, that dose should be omitted.  Patients must record the time and 
amount of each dose taken (or alternat ively, the time and amount of the dose missed or vomited) 
in a daily diary .
For Part G, patients shoul d receive fulvestrant according to the study schedule .  For patients 
already receiving fulvestrant at time of study  entry, the fulvestrant dose on Cy cle 1 Day 1 shoul d 
correspond approximately to the expected date for its monthly administration andfulvestrant 
shoul d not be administered on Cycle 1 Day  15.
For Part G, f ulvestrant 500 m g shoul d be administered intramuscularly into the buttocks slowly  
(1to2 minutes per inject ion) as two 250-mginjectio ns, one in eac h buttock ; however, for 
patients wi th moderate hepatic impairment (defined as Child -Pugh C lass B), fulvestrant 250 mg 
shoul d be administered intramuscularly  into the buttock sl owly  (1 to2 minutes) as one 250-mg
inject ion.
Patients will  receive 2 cycles of LY2835219 unless one or m ore of the criteria for 
discontinuat ion (refer to Section 5.3.1 ) are fulfilled ; the follow-up peri od for pos tstudy 
evaluat ion will be 30 ±
7days from the date of the last dose of study  drug received.  A p atient 
may receive more than 2 cy cles of treatm ent only if 1) none of the criteria for discont inuat ion 
have been fulfilled, and 2) the investigator, in consultation with the Lilly CRP, determines that 
the patient is experiencing clinical benefit from treatm ent.
For Cy cle 2 and bey ond, a delayof ≤7 days in the start of a cy cle (Day  1) for justifiable reasons 
(for example, inclement weather, holidays, or weekends) other than toxicit ywill be permitted 
and does not constitutea protocol vio lation.
For Cy cle 2 and bey ond, a delayof ≤14 days in the start of a cy cle (Day  1) to allow for recovery  
from toxicitywill be permitted and does not constitute a protocol vio lation(refer to 
Secti on6.2.4.2 ).
6.2.2. Dose -Escalation P hase
The dose wasescalated fo llowing assessment of toxicit y using the standard scoring system, 
Commo n Termino logy Criteria f or Adverse Events (CTCAE  established by the 
National Cancer Inst itute (NCI).  Any AEs possibly  related to LY28 35219 were considered as
toxicities.
For t he dose -escalat ion phase, Table JPBA. 6.
1summarizes the dose levels co mpleted for the 
once daily  schedule (50 to 225 m g every 24 hours) and the proposed dose levels for the twice 
daily  schedule (75 to 450 m g every  12 hours ).  Three patients were planned for treatment at each
dose l evel; however, the exact number of pat ients treated at a specific dose level depend ed, as 
discussed below,
on the number of pat ients within the cohort who experienced a DLT.   If a
patient in a given cohort experience da DLT during Cycle 1 , then subsequent patients were
enrolled sequent ially.
CCI
I3Y-MC-JPBA (j)Phase 1 Oncology Protocol Amendment Page 31
LY2835219In all cohorts (including the first cohort), every  patient w asassess ed for toxi city (based on 
CTCAE  grading) on Day s 15 and 29 of Cyc le1.  Except for the init ial cohort, 
patients in all subsequent cohorts were enrolled concurrently.
Table JPBA .6.1. Dose -Escalation Scheme for Study I3Y-MC-JPBA
Cohort Patients/Cohort LY2835219 Dose
1 3 50 mg Q24H
2 3 100 mg Q24H
3 3 150 mg Q24H
4 3 225 mg Q24H
5 3 75 mg Q12H
6 3 100 mg Q12H
7 3 150 mg Q12H
8 3 200 mg Q12H
9 3 275 mg Q12H
10 3 350 mg Q12H
11 3 450 mg Q12H
Abbreviations:  Q24H = every 24 hours, Q12H = ever y 12 hours .
Note:  Cohorts 1 -4 received study drug Q24H on the once daily schedule .
The dose -escalation phase was guided by safet y assessments fro m Days -3 through 29 of Cycle 1 
for all patients in the coh ort and also by  the em erging PK data from  previ ous cohorts.  I f none of 
the pati ents in a cohort experienced a DLT, dose escalat ion could o ccur to the next prespecified 
dose l evel.  For all cohorts, if safet y assessments and/or the emerging PK data indicat ed ei ther 
that dose escalation should occur to a dose level lo wer than the next prespecified dose level or 
that dose de -escalation should occur to a dose level lower than the current dose level, then safet y 
assessments and/or the emerging PK data could be used to select an alternate dose level wit hin 
these constraints.  Dose escalation occurred until the MTD (defined in Sect ion 6.2.2.1 ) was 
establishe d at 200 m g every 12 hours for the twice daily  schedule.
Dose escalat ion, unless guided by the emerging PK data as described above, proceed edas 
indicated in Table JPBA. 6.1until 1 patient experience da DLT; thereafter, all subsequent patients 
in that cohort w ereenrolled sequent ially.  If a DLT occur redin only 1 of 3 patients at a given 
dose l evel, up to 6 pati ents couldbe treated at that dose level; however, a total of 6 patients had 
tobe treated at that dose level wit hout further occurrences of a DLT before dose escalation could
resum e.  If a DLT occur redin more than 1 patient at a given dose l evel, then the MTD hadbeen 
exceeded and both dose esc alation and enrollment to the cohort cease d.  However, fo llowing 
discussio nand agreement with invest igators , addit ional pat ients couldbe treated at intermediate 
doses between the previous dose level and the dose level that exceeded the MTD to define the 
MTD more precisely.
CCI
I3Y-MC-JPBA (j)Phase 1 Oncology Protocol Amendment Page 32
LY2835219In thi s study , intrapati ent dose escalation wasnot permitted and dose escalat ion to the next 
cohort could notoccur wi thout pri or discussio n and agreem ent between the invest igator and the 
responsible Lilly CRP.
6.2.2.1. Dose -Limiting Toxicity Determination and Maximum Tolerated Dose 
Definition
Dose -limit ing toxicit y (DLT) is defined as an AE occurring between Day  -3 and Day  29 of Cycle 
1 for a patient enrolled in Part A that is possibly related to the study  drug and fulfills any one of 
the following cri teria:
Grade 3 or 4 nonhematological toxicit y according to the NCI Commo n 
Termino logy Cri teria for Adverse Events (CTCAE  except for 
nausea, vo miting, diarrhea, or electrolyte disturbance.
Grade 3 or 4 nausea, vo miting, diarrhea, or el ectroly te disturbance that persists 
more than 2 days despite maximal supportive intervent ion.
Grade 4 hematological toxicit y that persi sts m ore than 5 days.
Grade 3 or 4 thrombocy topeni a with bleeding .
Grade 3 or 4 neutropenia with fever.
Invest igators, t ogether wi th the Lilly  CRP, can declare a DLT if a patient is experiencing 
increasing toxicit y during treatm ent, and i t becom es clear that i t is not goi ng to be possible to 
complete the treatm ent wi thout exposing the patient to excessive risk.
A DLT -equiva lent toxicit y is defined as an AE that woul d have met the criteria for DLT if it had 
occurred during Cycle 1 for a patient enrolled in Part A but that occurs between 1) Day 1 and 
Day 28 of  Cycle 2 and bey ondfor a pati ent enrolled in Part A ; 2) Day  1 and D ay 29 of Cycle 1 
for a pati ent enrolled in Parts B, C, D, E, F,or G; or 3) Day 1 and Day  28 of Cycle 2 and bey ond 
for a pati ent enrolled in Parts B, C, D, E, F,or G.
Maximum tol erated dose (MTD) is defined as the highest dose level at which less than 33% of 
patients experience a DLT during Cycle 1.
6.2.2.2. Biologically Effective Dose
Pharmacokinet ic(PK) and PD data will be used for estimating the bio logically effective dose
(BED). For the purpose of this study, the BED is defined as the lowest dose that achieves a 
minimum o f 30 to 50% inhibit ion of CDK4/6 (measured by pRb and topoIIα) in surrogate tissues 
(hair fo llicles or skin) at steady  state.  This level of CDK4/6 inhibit ion corresponds to that 
observed in mouse preclinical experiments at the lowest d ose achieving tumor growth delay . 
Nonclinical PK/PD m odeling predicts that a dose of 150 -300 m g of LY2835219 administered 
every 24 hours will produce the minimum level of CDK4/6 inhibit ion that has been associated 
with tumor growth delay  in preclinical  efficacy  studi es.
6.2.3. Dose Confirmation Phase (Parts B, C, D, E, F,and G )
After the MTD has been ident ified in Part A , at least 15and up to 45 -60patients will be enro lled 
in each of the 6tumor-specific expansio ns:  Part B (non –small cell lung cancer), Part C
CCI
I3Y-MC-JPBA (j)Phase 1 Oncology Protocol Amendment Page 33
LY2835219(glioblastom amultiform e), Part D (breast cancer), Part E (melanoma) , Part F (col orectal  cancer) ,
and Part G ( HR+ breast cancer) .
During the dose confirmat ion phase, patients may enroll concurrent ly and will be treated at a 
dose no greater than the MTD (200 m g every 12 hours ).  Patients enro lled under JPBA 
amendment (f) who are still receiving LY2835219 at a dose of 150mg every 12 hours may, at 
the discret ion of the invest igator, be escalated to 200 mg every 12 hours.  P atients enro lled under 
JPBA amen dment (g)or subsequent amendment shoul d initially receive LY2835219 at a dose of 
200mg every 12 hours .  For all pat ients,dose adjustm entsare permitted as outlined in
Secti on6.2.4.1 .
IfDLT -equivalent toxicit ies occur in 33% or more of patients within a tum or-specific cohort 
expansio n, then invest igators and the Lilly CRP will assess the nature and severit y of these 
toxicities.  No addi tional patients will be accrued unt il thissafety review is com pleted and a 
decisio n is made either to con tinue at the current dose or to deescalate the dose and define a new 
dose for the expansio n phase.  Th e safetyreview and decisio n will be documented in writ ing.
During the dose confirmat ion phase, paired tumor biopsies should be obtained, whenever 
clinically feasible, before (Day  
-14 to Day  -4) and after (Day  8 to Day  22) administration of 
study  drug in Cycle 1.
6.2.4. Dose Adjustments
6.2.4.1. Dose Adjustments
Table JPBA. 6.2is a guidance for management of treatm ent-emergent, rel ated, and clinically 
significant toxicities ofLY2835219 .
Table JPBA .6
.2. Toxicity Dose Adjustments and Delays of LY2835219
Toxicity Type Toxicity Profile and Severity Dose Suspension Dose Reduction
Hematologic Toxicity Grade 3 Dose MUST be 
suspended until toxicity 
resolves to at least Grade 
2.Dose reduction is NOT
required.
Hematologic Toxicity Recurrent aGrade 3 Dose MUST be 
suspended until toxicity 
resolves to at least 
Grade 2.Dose MUST be reduced 
by 1 dose level. 
Hematologic Toxicity Grade 4 Dose MUST be 
suspended until toxicity 
resolves to at least Grade 
2.Dose MUST be reduced 
by 1 dose level.
I3Y-MC-JPBA (j)Phase 1 Oncology Protocol Amendment Page 34
LY2835219Toxicity Type Toxicity Profile and Severity Dose Suspension Dose Reduction
Hematologic Toxicity:  
If patient requires 
administration of 
blood cell growth 
factorsRegardless of severity 
(Use of growth factors 
according to ASCO 
Guidelines)Dose MUST be 
suspended for at least 
48hours after the last 
dose of blood cell growth 
factors was administered 
and until toxicity 
resolves to at least 
Grade 2.Dose MUST be reduced 
by 1 dose level unless 
already performed for 
incidence of toxicity that 
led to the use of growth 
factor.
Non-hematologic 
Toxicity b
(except diarrhea , 
ALT /AST increased , 
and ILD/Pneumonitis )Persistent or recurrent Grade 2 
that does not resolve with 
maximal supportive measures 
within 7 days to baseline or 
Grade 1Dose MUST be 
suspended until toxicity 
resolves to either 
baseline or Grade 1.Dose MUST be reduced 
by 1 dose level.
Non-hematologic 
Toxicity b
(except diarrhea , 
ALT /AST increased , 
and ILD/Pneumonitis )Grade 3 or 4 Dose MUST be 
suspended until toxicity 
resolves to either 
baseline or Grade 1.Dose MUST be reduced 
by 1 dose level.
Diarrhea  Grade 2 that does not resolve 
within 24 hours to at least
Grade 1Dose MUST be 
suspended until toxicity 
resolves to at least Grade 
1.Dose reduction is NOT
required.
Diarrhea Persistent or recurrent Grade 2 
that does not resolve with 
maximal supportive measuresDose MUST be 
suspended until toxicity 
resolves to at least Grade 
1.Dose MUST be reduced 
by 1 dose level.
Diarrhea Requires hospitalization or 
Grade 3 or 4Dose MUST be 
suspended until toxicity 
resolves to at least Grade 
1.Dose MUST be reduced 
by 1 dose level.
ALT /AST Increased Persistent or recurrent a
Grade 2 (>3.0 -5.0×ULN ), or
Grade 3 (>5.0-20.0×ULN) cDose MUST be 
suspended until toxicity 
resolves to baseline or 
Grade 1.Dose MUST be reduced 
by 1 dose level.
ALT /AST Increased Grade 4 (>20.0×ULN) LY2835219 therapy 
MUST be discontinued.LY2835219 therapy 
MUST be discontinued.
ALT /AST Increased 
with increased total 
bilirubin, in the 
absence of cholestasis≥Grade 2 increased ALT /AST
(˃3.0 ×ULN) with
total bilirubin >2 ×ULNLY2835219 therapy 
MUST be discontinued .LY2835219 therapy 
MUST be discontinued .
ILD/Pneumonitis d Grade 2 that persists or recurs 
despite maximal supportive 
measures and does not return 
to baseline or Grade 1 within 7 
daysDose MUST be 
suspended until toxicity 
resolves to baseline or 
Grade ≤1.Dose MUST be reduced 
by 1 dose level.
ILD/Pneumonitis d Grade 3 or 4 LY2835219 therapy 
MUST be discontinued .LY2835219 therapy 
MUST be discontinued .
I3Y-MC-JPBA (j)Phase 1 Oncology Protocol Amendment Page 35
LY2835219Abbreviations:  ALT = alanine aminotransferase ; ASCO = American Society of Clinical Oncology; AST = aspartate 
aminotransferase ; ILD = interstitial lung disease; ULN = upper li mit of normal.
Note:  MUST =mandatory.
aDetermination of persistent events will be at the discretion of the investigator .  Recurrent toxicity refers to the 
same event occurring within the next 8 weeks (as measured from the stop date of the preceding even t).  As a 
general guidance, based on the benefit/risk balance assessment per the investigator, for a patient who experiences 
a new episode of Grade 3 hematologic toxicity after more than 8 weeks following the last episode of same 
Grade 3 hematologic toxici ty, the investigator may consider resuming the patient on the same drug dose should 
the patient satisfy t he following conditions:
shows stable hematologic counts (Grade ≤2) during that timeframe
has absence of any signs or risk of infection
is benefiting from study treatment
bAdditional guidance for renal and hepatic monitoring is provided in Sections 7.1.3.2 and 7.1.3.1 .
cGrade 3 ALT /AST increased is a trigger for additional assessments and possibly hepatic monitoring.  See Section 
7.1.3.1 for additional guidance for hepatic monitoring .
dAdditional guidance forILD/pneumonitis monitoring is provided in Section 7.1.3.4 .
Dose adjust ments as outlined in TableJPBA. 6.3are allowed both wi thin a cycle and b etween 
cycles.  LY2835219 dose alterations (omissio n, reduction, and discont inuat ion) should not be 
based so lely on the presentati on of  serum  creat inine values, because these may not reflect actual 
renal funct ion.  Further informat ion can be found in the S ection 3.2.4 of the LY2835219 IB.
If a patient who, in the judgment of the investigator, is receiving clinical benefit fro m study  
therapy  requi res further dose reduction than is outlined in TableJPBA. 6.
3, then the investigator 
must discuss wi th the Lilly  CRP pri or to any  further dose reduction.
For pati ents requi ring dose reduction(s), re -escalat ion to a prior dose level is permit ted only  after 
consultation wit h the Lilly CRP.
Dose omissio ns are allowed within a cycle.  If apatient requi res omissi on of more than 25% of 
doses during a cycle for tolerabilit y, then treatm ent may cont inue if the invest igator determines 
the pati entis receiving clinical benefit.
TableJPBA .6
.3. Dose A djustments of LY2835219 for Study I3Y -MC-JPBA
Dose Adjustment Oral Dose Frequency
0 200 mg Every 12 hours
1 150 mg Every 12 hours
2 100 mg Every 12 hours
3 75 mg Every 12 hours
For pati ents in Part G with moderate hepatic impairment (defined as Child -Pugh Class B), 
fulvestrant 250 mg should be administered intramuscularly into the buttock slowly (1 to 2 
minutes) as one 250 -mg inject ion, according to the st udy schedule.  In the event that fulvestrant 
must be discont inued, a patient may cont inue to receive LY2835219.
I3Y-MC-JPBA (j)Phase 1 Oncology Protocol Amendment Page 36
LY28352196.2.4.2. Dose Delays
Before the start of each cycle, hematol ogic toxi city possibly related to LY2835219 must resolve 
to either baseline or at least Grade 2.
Before the start of each cycle, non-hematol ogic toxicit y (except al opeci a and fat igue) possibly 
related to LY2835219 must resolve to either baseline or at least Grade 1.
The start of a cy cle may  be delayed to allow sufficient time for recovery from toxicity possibly  
related to study  drug .  Pati ents not recovering from such toxicity within 14days beyo nd the l ast 
day of the pri or cy cle shoul d be considered for discontinuat ionfrom the study .
6.3. Method of Assignment to Treatment
Patients who m eet all cri teria for enrollment will be assigned to receive LY2835219 in this study .  
Prior to enrollment into the study , an eligibilit y check m ust be conducted (for every  patient) 
between the invest igational site and the Lilly  clinical  research personnel, to confirm tha t the 
patient meets all enrollment criteria.  Upon confirmat ion of eligibilit y, the sponsor will confirm 
the dose, cohort, and identificat ion number assignment for each patient.  No patients can be 
enrolled into the next cohort without prior discussion and agreem ent with the responsible Lilly 
CRP.
6.3.1. Continued Access
Parti cipants who are still on study  drug may  cont inue to receive study drug during the continued 
access period if they are experiencing clinical benefit and no undue risks.  Lilly will notify 
investigators when the continued access period begins .  Lilly may  allow parti cipants to enroll in 
a “rollo ver” protocol  to provi de long-term continued access for participants enrolled in this 
study .
Patients are not required to sign a new informed consent form (ICF) before treatment is provided 
during the continued access period.
During the continued access period, all adverse events (AEs), serious adverse events (SAEs), and 
study  drug exposure will be reported on the case report form (CRF).  Serious adverse ev ents will  
also be reported to Lilly Glo bal Pat ient Safety  (see Secti on 7.1.2 ).  In the event that an SAE 
occurs, Lilly  may request addi tional information (such as l ocal laboratory  resul ts, concomi tant 
medicat ions, and hospitalizat ions) in order to evaluate the reported SAE.
Invest igators will perform any other standard procedures and tests (locally) needed to treat and 
evaluate patients; however, the c hoice and timing of the tests will be at the investigator’s 
discreti on.  Lilly  will not routi nely co llect the results of these assessments.
The patient’s cont inued access to study drug will end when a criterion for discont inuat ion is met 
(Secti on 5.3).  Continued access fo llow-up will begin the day  after the pati ent and invest igator 
agree to discontinue study  drug and last approximately  30 days .
Patients who are in short -term follow
-up when the continued access period begins will cont inue 
in short -term follow-up unt il the 30 -day short -term fo llow-up visit is co mpleted.
I3Y-MC-JPBA (j)Phase 1 Oncology Protocol Amendment Page 37
LY2835219In all cases, no fo llow-up procedures will be performed for a patient who wit hdraws informed 
consent unless he or she has explicit ly provided permissio n and consent.
6.4. Blinding
This is an open -label study .
6.5. Concomitant Therapy
For Part G, concomitant therapy  with fulvestrant i s permitted.
No ot her chemotherapy, immunotherapy, or experimental medicat ions arepermitted while the 
patients are on thi s study .  Hormone replacement therapy init iated before study  entry  may be 
continued but should be considered for discont inuation .  Palliat ive radiothera py, unless requi red 
due to progressive disease, is permitted during the study .  Disease progression requiring specific 
antitumor therapy  will necessitate early discontinuation fro m the study .  Appropri ate 
docum entati on for all form s of prem edicat ions, supp ortive care, and concomitant medicat ions 
must be captured for each cy cle on the case report form.
Patients shoul d receive full supportive care during th is study .
Growth factors may  be administered in accordance with American Society  of Clinical Onco logy 
(ASCO) guidelines ,if clinically indicated (Smit h et al . 2015; Rizzo et al . 2010 ). See Table 
JPBA. 6.2for dose adjustments and delays related to administration of growth factors . 
Transf usion therapy  is permitted during this study .
Modulators of CYP3A
LY2835219 is extensively  metabo lized through oxidat ion by CYP3A. In clinical drug interaction 
studi es, 
coadministration of clarithro mycin, a strong CYP3A inhibitor, increased exposure (AUC) 
of LY2835219 by 3.4- fold (Study  I3Y-MC-JPBE), and 
coadministration of rifampin, a strong CYP3A inducer, decreased exposure of 
LY2835219 by 95% (Study  I3Y-MC-JPBF).  
Strong inhibitors of CYP3A (given via non
-topical routes of administration) should be 
subst ituted or avoided if possible ( Attachm ent 8). This includes grapefruit or grapefruit juice. In 
particular, avo id oral administration of the very strong CYP3A inhibitor, ketoconazole.
If coadministration with a strong CYP3A inhibitor is unavo idable, investigators should reduce 
the dose of LY2835219 by 50 mg at the start of CYP3A inhibitor treatment. That is, for patients 
receiving 150 mg twice daily, reduce the dose to 100 mg twice daily . For pati ents who have 
already dose reduced to 100 mg twice daily for tolerabilit y, reduce the dose further to 50 mg 
twice daily . Alternatively, the investigator may  consider suspending LY2835219 for the duration 
of the CYP3A inhibitor medication. Dose suspensions ≥28 days must be discussed with Lilly 
CRP/CRS.
I3Y-MC-JPBA (j)Phase 1 Oncology Protocol Amendment Page 38
LY2835219Upon discont inuat ion of the strong CYP3A inhibit or, the dose of LY2835219 may be re -
escalated to the dose that was used before starting the strong inhibitor after a sufficient washout 
period (3 -5 half -lives of the str ong inhibitor). Re -escalat ion of the LY2835219 dose requires 
review and approval fro m Lilly CRP/CRS.
Inducers of CYP3A should be subst ituted or avoided if possible ( Attachm ent 8). 
Coadministration wit h a CYP3A inducer ≥28 days must be discussed with Lilly CRP/CRS.
Transporter Substrates
At clinically relevant concentrations, LY2835219 inhibits the transporters P -glycoprotein, breast 
cancer resistance protein, organic cat ion transporter 2 (OCT2) , multidrug and toxin extrusi on 
protein 1 (MATE1), and MATE2- K. The observed serum creatinine increase in clinical studies 
with LY2835219 is likely due to inh ibition of tubular secret ion of creatinine via OCT2, MATE1, 
and MATE2
-K.In vivo interactions of LY2835219 with narrow therapeutic index substrates of 
these transporters, such as digoxin and dabigatran, may occur.
6.5.1. Supportive Management for Diarrhea
In the event of diarrhea while a patient is receiving LY2835219 , supportive measures should be
initiated as early as possible .  These include the fo llowing:
At the first sign o f loose stools, the patient should init iate anti -diarrh eal therapy (for 
example, loperamide), and notify the investigator for further instructions and appropriate 
follow-up.
Patients shoul d also be encouraged to drink fluids (for example, 8 to 10 glasses of clear 
liquids per day ).
Site personnel should assess response wi thin 24 hours.
If diarrhea does not resolve with ant i-diarrheal therapy  within 24 hours to at least
Grade 1, then dosing should be suspended unt il dia rrhea is resolved to at least Grade 1.
When LY2835219 recommences, dosing should be adjusted as outlined in Table 
JPBA. 6.2.
Forsevere cases of diarrhea, the measurement of neutrophil counts , body temperature
,and the
proactive management of diarrhea wit h ant idiarrheal  agents shoul d be considered.
If diarrhea is severe (requiring IV rehydration) and/or associated with fever or severe
neutropeni a, broad -spectrum ant ibiotics such as fluoroquinolones shoul d be co nsidered .
Patients wi th severe di arrhea or any  diarrhea associated wi th severe nausea or vomit ingshoul d 
be carefully mo nitored and given IV fluid (IV hy dration) and electroly te repl acement as 
clinically indicated .
I3Y-MC-JPBA (j)Phase 1 Oncology Protocol Amendment Page 39
LY28352196.6. Treatment Compliance
Patient com pliance wi th study  medicat ion will be assessed at each visit by review o f the pati ent 
diary, direct questi oning, and count ing of returned solid oral dosage units.   Deviat ion(s) fro m the 
prescribed dosage regimen should be recorded on the Case Re port Form  (CRF).
The patient must take 75% of the planned doses in a cycle to be deemed compliant with study  
drug administration.  Similarly , a pati ent m ay be consi dered noncom pliant if he or she is judged 
by the investigator to have intent ionally  or repe atedly taken more than the prescribed amount of 
medicat ion.  Any  missed doses during a cy cle will  be omi tted and not repl aced.  In the event of a 
missed dose, a patient should resume and cont inue dosing beginning with the next scheduled 
dose.  Potential di scont inuat ion of a patient due to study  drug noncom pliance will  be discussed 
between the invest igator and the Lilly CRP before making the final determinat ion for 
discontinuat ion.  If a patient is discont inued due to study drug nonco mpliance, the patient ma y be 
replaced.
I3Y-MC-JPBA (j)Phase 1 Oncology Protocol Amendment Page 40
LY28352197. Safety , Pharmacokinetic, Pharmacody namic, and 
Efficacy Data Collection
7.1. Safety Evaluations
The safe ty and tol erabilit y of LY2835219 have been assessed in nonclinical toxico logy studi es 
and the results from these studies are detailed in the IB .  Thi s Phase 1 study  contains a detailed 
safet y monitoring plan that will permit init ial characterizat ion ofthe safet y profile of LY2835219
in patients.  Study  procedures and their timing , including tolerance limit s for timing ,are 
described in the Study Schedule (Attachment 1 ).
Blood sam ples and ECGs will be collected at the times specified in the Study  Schedule
(Attachm ent 1 ).  Laboratory  tests including hematology , chemistry , and special  blood tests will 
be performed.  A serum  pregnancy  test will be administered to females wit h child bearing 
potenti al. Attachm ent 2 lists the specific laboratory tests that will be performed for this study.  
Enrollment and treatment decisio ns may be based upon resul ts of tests performed locally.  If 
local laboratory  tests are used for this purpose, then a duplicate specimen must be submitted to 
the central  laboratory .  Discrepancies between local and central  laboratory and ECG resul ts that 
may have an impact on eligibilit y ortreatm ent decisi ons will not be considered protocol 
violations.  When both a local and central laboratory  resul t are obtained and there is a 
discrepancy  in these laboratory  values, the l ocal laboratory  values will be used for determining a 
DLT, after disc ussion with the study  invest igator(s).
Samples co llected for specified laboratory tests will be destroyed wit hin 60 days of receipt of 
confirmed test results.  Certain samples may be retained for a longer period, if necessary, to 
comply with applicable law s, regul ations, or l aboratory  certificat ion standards.
If a patient’s dosage is reduced or treatment discontinued as a result of an AE, study -site 
personnel must clearly  report to Lilly  or its desi gnee via CRF the circumstances and data leading 
to any  such dosage reduction or discont inuat ion of treatm ent.
All conco mitant m edicat ions should be recorded throughout the patient’s participat ion in the 
study , until conclusio n of the study  follow-up period.
7.1.1. Safety Data Collection and Review
Invest igators are respo nsible for monitoring the safety of pat ients who have entered into this 
study  and f or alerting Lilly  or its designee to any  event that seem s unusual , even if this event 
may be considered an unant icipated benefit to the patient .  The invest igator is respons ible for the 
appropriate medical care of the patient during the study .
The invest igator, monitor, and sponsor will review the collected data regularly for evidence of 
AEs.  All pat ients will be assessed routinely for AEs as outlined in the study  schedule. All AEs
observed on study  will be graded using the Common Termino logy Criteria f or Adverse Events 
(CTCAE 
The invest igator remains responsible for fo llowing , through an appropriate healt h care option, all 
AEs that are SAEs or that caused the patient to di scontinue before complet ing the study .  The 
CCI
I3Y-MC-JPBA (j)Phase 1 Oncology Protocol Amendment Page 41
LY2835219patient shoul d be f ollowed unt il the event is reso lved, the event is no longer considered to be 
drug-related, the event beco mes stable or returns to baseline, a new treatm ent is initiated for the 
patient, or the pati ent di es or is l ost to foll ow-up.  Frequency of AE and SAE follow-up 
evaluat ion is left to the discret ion ofthe investigator.
Invest igators or their designees must document their review of each laboratory report.
This study  requi res ECG m onitoring at both baseline and prespecified time points (see
Attachm ent 1 ).  For each subject 12 -lead digital ECGs will be obtained as single ECGs according 
to the Study  Schedule ( Attachment 1 ).  Subjects must be supine for approximately 5 to 
10minutes before ECG collect ion and remain supine during ECG collection.   ECGs m ay be 
obtained at addit ional times ,when deemed clinically  necessar y.  Collection o f more ECGs than 
expected at a particular time po int is allowed when needed to ensure high qualit y records.
ECGs will be interpreted by  a qualified physician ( the invest igator or qualified designee) at the 
site as soon after the time o f ECG collect ion as possible, and ideally while the subject is st ill 
present, to determine whether any  clinically relevant findings are present.
After enro llment, if a clinically significant increase in the QTc Binterval from baseline, or other 
clinically significant quantitative or qualitative change fro m baseline, i s present, the invest igator 
will assess the subject for symptoms ( for example, palpitations, near syncope, syncope) and to 
determine if the subject can continue in the study .  The invest igator or qualified designee is 
responsible for determining if any change in subject management is needed and must document 
his/her review of the ECG printed at the time o f evaluation.
All digital ECGs will be electron ically transmitted to a central ECG laboratory designated by 
Lilly.  A cardio logist at the central  ECG l aboratory will then conduct a full overread on the ECG 
(including all intervals); a report based on data from this analysis will be issued to the 
invest igative sit e.
It is recognized that ECG interpretations by  the investi gator (or qualified designee) and by the 
cardi ologist at the central  ECG l aboratory  may be different.  When there are differences in ECG 
interpretati on between the invest igator (or quali fied desi gnee) and the cardi ologist at the central 
ECG laboratory , the interpretati on of  the investi gator (or qualified designee) will be used for 
study  entry  and immediate subject management .  Interpretations fro m the cardi ologist at the 
central  ECG l aboratory  will be used for data analysis and report writing purposes.
The invest igator (or qualified designee) must document his/her review of the ECG printed at the 
time of evaluat ion, the final over -read ECG report issued by the central ECG laboratory , and a ny 
alert reports.
7.1.2. Adverse Events
Lilly has standards for reporting AEs that are to be fo llowed regardl ess of applicable regulatory  
requi rements that m ay be less stringent.  A clinical trial AE is any  untoward medical occurrence 
in a pati ent or clinical inv estigation subject administered a pharmaceut ical product and which 
does not necessarily  have a causal  relati onship wi th this treatm ent.  An AE can therefore be any  
I3Y-MC-JPBA (j)Phase 1 Oncology Protocol Amendment Page 42
LY2835219unfavorable and unintended sign (including an abnormal laboratory  finding), symptom, or 
disease tem porally associ ated wi th the use of m edicinal (invest igational) product.   Any clinically 
significant findings from labs, vital sign measurements, and so on that occur should be reported 
to Lilly  or its desi gnee as an AE using the same guidelines and schedules as those for AEs.   Lack 
of drug effect is not an AE in clinical studi esbecause the purpose of the clinical study is to 
establish drug effect.
The invest igator, monitor, and sponsor will review the collected data regularly for evidence of 
AEs.  All pat ients will be assessed routinely for AEs as outlined in the study  schedule.  All AEs
observed will be graded using CTCAE 
The Nat ional Cancer Inst itute (NCI) -CTCAE  will serve as the reference document for 
choosing appropriate termin ology for,and grading the severit y of, all AEs and other symptom s.  
For AEs wi thout m atching termino logy within the NCI -CTCAE crite ria, the invest igator 
will be responsible for select ing the appropriate sy stem organ class and assessing severit y grade 
based on the intensit y of the event .  Note that both CTCAE term (actual or coded) and severit y 
grade must be selected by  study  site personnel and collected on the CRF.  This collection is in 
addition to verbat im text used to describe the AE.
In addit ion to collect ing the AE verbat im, the CTCAE term, and the CTCAE severit y grade, AE 
verbat im text will also be mapped by the sponsor or designee to corresponding termino logy 
within the Medical Dict ionary for Regulatory  Activities (MedDRA) dict ionary.
Cases of pregnancy that occur during maternal or paternal exposures to study  drug shoul d be 
reported.  Upon documentation of pregnancy , the pati ent m ust be rem oved from  the study  and 
treatm ent wi th study  drug m ust be stopped immediately.  Data on fetal outcome and 
breast feeding should be collected, if feasible, for regulatory  reporting and drug safet y evaluat ion.
For all enrolled pat ients, study site personnel will record the occurrence and nature of each 
patient’s pre -exist ing condit ions, including clinically  significant signs and symptoms o f the 
disease under treatment in the study .  While the pati ent is on study , site personnel will record any  
change in these pre -exist ing condit ion(s) and the occurrence and nature of any AEs.   All AEs 
related to protocol  proc edures are reported to Lilly or its designee.
After the informed consent document (ICD) is signed, all AEs possibly  related to protocol  
procedures are reported to Lilly or designee via electronic CRF (eCRF).  Regardless of 
relatedness to study drug(s), all AEs occurring while the patient is receiving study drug must be 
reported to Lilly  or its designee via eCRF.
Lilly or i ts desi gnee will  be alerted to AEs occurring 30 ±7 days after a patient is discontinued 
from the study  only  if the investi gator believes that the event m ay have been caused by  the study  
drug or protocol procedures.
If a patient's dosage is reduced or treatment is discontinued as a result of an AE, study  site 
personnel must clearly  report to Lilly  or its desi gnee via CRF /electroni c data entr y/designated 
data transmissio n methods , the ci rcumstances and data leading to any  such dosage reduction or 
discontinuat ion of treatm ent.
CCI
CCI
CCI
I3Y-MC-JPBA (j)Phase 1 Oncology Protocol Amendment Page 43
LY2835219The invest igator decides whether he/she interprets the observed safet y signals as eit her rel ated to 
disease, to the stu dy medication, study  procedure, or other concomitant treatment or pathologies.  
To assess the relat ionship of the AE to the study  drug, the fo llowing termino logies are defined:
Probably related:  a direct cause and effect relationship between the study tre atment and 
the AE i s likely.
Possibly related:  a cause and effect relat ionship between the study  treatm ent and the AE 
has not been demonstrated at this time and is not probable, but is also not impossible.
Does not know:   the investigator cannot determine
Not related:   without question, the AE is definitely not associated with the study  
treatm ent.
As per Lilly’s standard operating procedures all “probably  related,” “possibly related,” “does not 
know” AEs and SAEs will be defined as related to study  drug.
Any clinically  significant findings (including but not limited to vital signs, physical findings, 
laboratories, and ECGs ) that occur should be reported to Lilly or its designee on the eCRF.
7.1.2.1. Serious Adverse Events
Serious adverse event collect ion begins afte r the pati ent has signed the informed consent 
docum ent.  If a pati ent experiences an SAE after signing informed consent, but prior to receiving 
study  drug, the event will NOT be collected unless the investigator feels the event may have 
been caused by a pr otocol  procedure.   During therapy with study drug and for 30 ±7 days after 
the last dose of study  drug, all SAEs will be collected regardless of relatedness to study  drug or 
protocol  procedures.  Beyond 30 ±7 days from the last dose of study  drug , only  ongoing or new 
SAEs possibly related to study  drug or protocol procedures should be reported.
Previously  planned (pri or to si gning the ICF) surgeries should not be reported as SAEs unless the 
underlying medical condit ion has worsened during the course of the study .
Prepl anned hospitalizat ions or procedures for preexist ing condit ions that are already recorded in 
the pati ent’s m edical  history  at the time of study  enrollment shoul d not be consi dered SAEs.  
Hospitalization or prolongat ion of hospitalizat ion without a preci pitating clinical AE (for 
example, for the administration of study  therapy  or other protocol -requi red procedure) shoul d not 
be considered SAEs.
An SAE is any  AEduring thi s study  that resul ts in oneof the fo llowing outcom es:
death
initial or prol onged inpatient hospitalizat ion (except for study  drug 
administration)
a life- threatening experience (that is, immediate risk of dying)
persistent or significant disabilit y/incapacit y
congenital ano maly/birth defect
I3Y-MC-JPBA (j)Phase 1 Oncology Protocol Amendment Page 44
LY2835219considered significant by the invest igator for any other reason
Important m edical events that may not result in death, be life -threatening, or require 
hospi talizati on may  be considered SAEs when, based upon appropriate medical judgment, they  
may jeopardize the patient and may r equire medical  or surgi cal intervent ion to prevent one of the 
outcom es listed in this definit ion.
Serious adverse events due to disease progressi on, including death, shoul d not be reported unless 
determined by the invest igator to be possibly related to stu dy drug.
Study  site personnel  must al ert Lilly or i ts desi gnee of  any SAE within 24 hours of invest igator 
awareness o f the event via a sponsor -approved method.  Alerts issued via telephone are to be 
immediately  followed wi th official notificat ion on study -specific SAE forms.   The 24- hour 
notification requirement refers to the init ial SAE informat ion and all fo llow-up SAE information.
Drug -or procedure -related SAEs should be fo llowed until they  resolve, are no l onger considered 
to be drug related, become stable or return to baseline, the patient starts a new therapy , the 
patient dies, or the pati ent becom es lost to f ollow -up.
7.1.2.2. Adverse Event and Serious Adverse Event Reporting
7.1.2.2.1. Prior to Administration of Study Drug
Adverse event and SAE co llection begins afte r the pati ent has signed the ICF and has received 
study  drug.  If a pati ent experi ences an AE or SAE af ter si gning the inform ed consent, but prior 
to receiving study  drug, the event will not be collected unless the invest igator believes the event 
may have been caused by  a protocol  procedure.
7.1.2.2.2. On Study Drug
All AEs and SAEs, regardless of relatedness to study  drugs or protocol  procedures, occurring 
while the patient is receiving study  drug m ust be reported to Lilly  or its designee.  A patient is 
considered to be receiving study  drug from  the time he/she receives the first dose of study  drug 
to when he/she receives the last dose of study  drug.
7.1.2.2.3. Follow -Up Visit
All AEs and SAEs, regardless of relatedness to study  drugs or protocol  procedures, occurring 
during the follow-up visit must be reported to Lilly or its designee.  The follow -up visit starts 
following the last dose of study  drug.  At the end of the fo llow-up visi t, the pati ent will be 
requi redto have a safet y assessment ( Attachment 1).  The timing of this safet y assessment is 
30 ±7 days afte r the l ast dose of study  drug.
Following the safet y assessment , whi ch m arksthe end of the follow -up visit, the patient will be 
discontinued fro m the study , unless there is an ongoing AE or SAE that is possibly  related to 
study  drug.  In thi s instance, the patient should be followed in subsequent fo llow-up visit s unt il 
the even tis resolved, the event i s no l onger consider ed to be drug -related, the event becomes 
stable or returns to baseline, a new treatment is init iated for the patient, or the patient dies or is 
lost to foll ow-up.
I3Y-MC-JPBA (j)Phase 1 Oncology Protocol Amendment Page 45
LY2835219After the fo llow-up visit, only new AEs or SAEs that are considered possibly  related to study
drug or protocol procedures shou ld be reported to Lilly or its designee.
7.1.2.2.4. Summary of Adverse E vent/Serious Adverse Event Reporting 
Guidelines
The AE and SAE reporting guidelines are summarized in Table JPBA .7.1. Refer to 
Attachm ent 5for specific reco mmenda tions about reporting SAEs.
Table JPBA .7
.1. Adverse Event and Serious A dverse Reporting Guidelines for 
Study I3Y-MC-JPBA
Timing Types of AEs and SAEs Reported
Prestudy (baseline assessments)
(Starts at the signing of informed consent and ends 
just before the first dose of study drug)Preexisting conditions
Only AEs and SAEs possibly related to protocol 
procedures
On therapy
(Starts at first dose of study drug and ends at last dose 
of study drug)All AEs and SAEs regardless of relatedness
Follow -up Visit (Visit 801)
(Starts just after the last dose of study drug and ends 
when final safety assessments are completed [30 ±7 
daysafter last dose of study drug ])All AEs and SAEs regardless of relatedness
Beyond 30 ±7 days after last dose of LY 2835219 Only ongoing or new AEs and SAEs possibly related to 
study drug or protocol procedures
Abbreviations:  AE = adverse event ;SAE = serious adverse event .
Any SAE due to progressive disease (including death) shoul d not be reported unless the 
investigator also d etermines there is a possible contri bution related to the study  drug .
7.1.3. Safety Monitoring
The Lilly clinical research physician or clinical research scient istwill monitor safety  data 
throughout the course of the study .  Lilly will review SAEs within t ime frames mandated by 
standard operating procedures, and will review trends, laboratory  analy tes, and AEs at peri odic 
intervals.
7.1.3.1. Hepatic Monitoring
Liver testing ( Attachment 3 ), including ALT, AST, alkaline phosphatase (ALP) , total  bilirubin 
(TBL), di rect bilirubin (D. Bil ), gamma -glutamyl  transferase (GGT) , and creatine kinase (CK) , 
shoul d be repeated wi thin 2 to 4 days to confirm the abnormalit y and to determine if it is 
increasing or decreasing, if one or more of these condit ions occur:
I3Y-MC-JPBA (j)Phase 1 Oncology Protocol Amendment Page 46
LY2835219If a participant with baseline results of… develops the following elevation s:
ALT or AST <1.5× ULN ALT or AST ≥5× ULN or
ALT or AST ≥3× ULN concurrent with TBL ≥2× ULN
ALT or AST ≥1.5×ULN ALT or AST ≥3× baseline or
ALT or AST ≥2× baseline concurrent with TBL ≥2×ULN
Abbreviations:  ALT = alanine aminotransferase; AST = aspartate aminotransferase; TBL = total bilirubin; ULN = 
upper limit of normal.
If the abnormalit y persists or worsens, clinical and laboratory  monitoring and evaluat ion for 
possible causes of abnormal liver tests should be init iated by  the invest igator in consultat ion with 
the Lilly -designated m edical mo nitor.At a minimum, this evaluat ion shoul d include physical 
examinat ion and a thorough medical history , including symptom s, recent illnesses (for example, 
heart failure, systemic infect ion, hypotension, o r seizures), history  of concomi tant m edicat ions 
(including over -the-counter, herbal and dietary  suppl ements, history  of alcohol  drinking, and 
other substance abuse). In addit ion, the evaluation should include a blood test for prothrombin 
time internat ionalnorm alized rati o (PT -INR); serological tests for viral hepat itis A, B, C, E, 
autoimmune hepat itis; and an abdo minal imaging study  (for exam ple, ul trasound or CT scan).
Additional Hepatic Safety Collection
Addit ional safet y data should be co llected via the case report form (CRF) if 1 or more of the 
following condit ions occur:
In participants enrolled with baseline ALT or AST <1.5× ULN
Elevat ion of serum ALT or AST to ≥5× ULN on 2 or more consecutive blood tests
The combinat ion of elevated ALT or AST ≥3×ULN and elevated TBL ≥2×ULN
In participants enrolled with baseline ALT or AST ≥1.5
×ULN
Elevated ALT or AST ≥3×baseline on 2 or more consecut ive tests
The combinat ion of elevated ALT or AST ≥2×baseline and elevated TBL ≥2×ULN
In all study participants
Discontinuati on from study  treatm ent due to a hepati c event or abnormalit y of liver test s
Occurrence of a hepat ic event considered to be an SAE
7.1.3.2. Renal Function
LY2835219 has been shown to increase serum creatinine due to inhibit ion of renal tubular 
secretion o f creatinine wit hout affect ing cystatin C -calculated gl omerular fil tration rate (GFR) .  
Increases in serum creat inine occurred within the first 2 weeks of treatment, remained stable 
through the treatment period ,and were reversible upon treatment discont inuat ion.  If 
deteri oration of  renal funct ion is suspected, serum creatinine should not be the only measure 
used to assess a patient’s renal funct ion.  Local testing o f cystatin C for calculation o f GFR can 
be considered for a more thorough assessment of renal function.
I3Y-MC-JPBA (j)Phase 1 Oncology Protocol Amendment Page 47
LY2835219Dose adjust ment (omissio n, reducti on, or discont inuation) should not solely be based on 
interpretati on of  serum  creat inine values because these may not reflect renal function.  If 
deteri oration of  renal funct ion is suspected per the investigator’s clinical assessment, dose 
alterati on shoul d follow the protocol guidance for non -hematol ogical toxicities(Table 
JPBA. 6.2).
7.1.3.3. Venous Thromboembolic Events
VTE has been ident ified as an adverse drug reaction for LY2835219 in combinat ion with 
endocrine therapy .In the rando mized Phase 3 studies in patients with breast cancer treated with 
LY2835219 in co mbination wit h endocrine therapy (ET), a greater number of patients 
experienced VTEs in the LY2835219 plus ET arm  than in the placebo plus ET arm or ET alone 
arm. 
The m ajority of patients who experienced VTEs were treated with ant icoagulants. 
In studies with single -agent abemaciclib use in the metastati c breast cancer ( mBC )popul ation or 
other tumor ty pes, including non-small  cell lung cancer ( NSCLC ), no increased rates of VTEs 
were observed as co mpared to the incidence of VTEs for these particular patient populat ions who 
were treated with other ant icancer agents. At this time, the m echanism underlying the associat ion 
between LY2835219 and the occurrence of VTEs is not known. Moni tor pati ents for si gns and 
symptoms of deep vein thrombosis and pulmo nary embolism and treat as medically appropriate.
7.1.3.4. Interstitial Lung Disease/Pneumonitis
Interstitial lung disease /pneum onitis has been identified as an adverse drug reaction for 
LY2835219 .  Addit ional information is available in the IB.
Ask y our pati ents to report any  new or worsening pulmo nary symptoms such as dyspnea, cough, 
and fever ;and invest igate and treat as per your loca l clinical pract ice (including corticosteroids 
as appropri ate).If ILD/pneumo nitis is suspected, investigations may include imaging such as 
high-resolution computed tomography, bronchoalveolar lavage, and biopsy as clinically 
indicated.
Refer to Table JPBA. 6.2for guidance on dose adj ustm ents of LY2835219 forpatients with 
ILD/pneumo nitis. Discont inue LY2835219 in cases of severe (Grade 3 or 4) ILD/pneumo nitis.
7.1.4. Complaint Handling
Lilly co llects complaints on study  drug used in clinical trials in order to ensure the safet y of 
study  participants, m onitor quali ty, and f acilitate process and product improvement s.
Com plaint s related to concomitant drugs are reported directly to the manufacturers of those 
drugs in accordance with the package insert.
The invest igator or his/her designee is responsible for handling the fo llowing aspects of the 
complaint process in a ccordance with the instructions provided for this study :
recording a complete descript ion of the complaint reported and any associated 
adverse events using the study -specific co mplaint form s provi ded for this 
purpose
faxing the completed complaint form wit hin 24 hours to Lilly or its designee
I3Y-MC-JPBA (j)Phase 1 Oncology Protocol Amendment Page 48
LY2835219If the invest igator is asked to return the product for invest igation, he/she will return a 
copy  of the product com plaint form  with the product.
7.2. Sample Collection and Test ing
7.2.1. Pharmacokinetic Evaluations
Pharmacokinet ic (PK) samples will be co llected as specified in the Study Schedule (Attachm ent 
1)and PK and PD Sampling Schedule (Attachm ent 4)
Venous blood samples from all pat ients will be analyzed to measure concentrati ons of 
LY2835219 and i ts metaboli tes (LSN
2839567 [M2] , LSN 3106729 [ M18 ], and LSN 3106726 
[M20 ]).  For Part G only, venous blood samples from patients will also be analyzed to measure 
concentrations of fulvestrant.  Blood sam ples will be co llected throughout the study (Parts A, B, 
C, D, E, F, and G).  Separate samples are not required for the parent ,its metabo lites, and 
fulvestrant .  Instructions for the collection and handling of blood samples will be provi ded by the 
sponsor .
A maximum of 5 addit ional PK (blood) samples may be added or removed during the study  if 
warranted and agreed upon by  both the invest igator and sponsor.  For instance, if during Cycle 1 
or 2, the patient is in the clinic for management of his/her disease or study -related events, 
additional PK (blood) samples, not to exceed 5 per pati ent,may be co llected fo llowing 
docum ented di scussio ns between the invest igator and sponsor.
Plasma PK samples (from venous blood) will be analyzed at a laboratory  designated by  the 
sponsor.  Concentrations of LY2835219 and its metabolites (LSN 2839567 [M2] , LSN 3106729 
[M18 ], and LSN 3106726 
[M20 ]) will be assayed using a validated liquid chromatography  with 
tandem  mass spectrometry  (LC/MS /MS) method.  For Part G, concentrations of fulvestrant will 
be assayed using a validated LC/MS /MS method.  Bioanaly tical samples collected to m easure 
study  drug concentrati on and m etabo lism, and/or protein binding, will be retained for a 
maximum o f 2 years fo llowing last pati ent visi t for the study .
CCI
I3Y-MC-JPBA (j)Phase 1 Oncology Protocol Amendment Page 49
LY28352197.2.2. Pharmac odynamic Evaluations 
Pharmacodynamic (PD) samples will be co llected as specified in the Study  Schedule 
(Attachm ent 1 ) and PK and PD Sampling Schedule ( Attachment 4).  Refer to these attachments 
(including foot notes) for important informat ion about these samples and their co llection.
Hair follicles will be co llected for the measurement of the fo llowing cell cycle bio markers :  total 
retinoblastoma protein (Rb), phosphorylated retinoblastoma protein (p -Rb) and top oisomerase II 
alpha (topoIIα).
In addit ion, skin andtumor biopsies will  be collected pre -and post -treatm ent as suppl emental  
tissue for m easuring these bio markers.  Due to the absence of fixed timing for tumor biopsies, 
which should be obtained (whenever clinically feasible) only during dose confirmat ion (Parts B, 
C, D, E, F,and G ), these are not indicated in the PK and PD Sampling Schedule (
Attachment 4).
Precut, unstained slides from any available archival specimen of the patient’s tumor will be 
requested for bio marker related studies.  In addit ion, tum or biopsy  samples will be obtained from 
patients enrolled in Part s B, C, D, E, F,and G when feasible and safe.  Although it i s preferred 
that tumor tissue bi opsies be taken by  either core needl
e or excisi onal biopsy , fine needle aspirate 
(FNA) biopsies will be acceptable.  The size o f the sam ple will be dependent upon the procedure 
utilized to obtain the sample.  These bio marker -related studies will include, but not be limited to, 
IHC, protein, and/or genetic an alyses of the tumor specimens.
For purpose of comparison, in the event a patient participat ing in this clinical trial elects to have 
a surgi cal procedure that involves removing some part of their tumor, a formalin -fixed paraffin -
embedded (FFPE) tumor tissue sample, or duplicate paraffin block, will be requested.
The goal of obtaining these samples will be to obtain a better understandin g of molecular tum or 
markers that might help predict which cancer pat ients are more likely to res pond to treatment 
with LY2835219.
Instructi ons and supplies required for the collect ion and shipment of the patients’ samples will be 
provi ded by the sponsor. Sample handling and shipment to the central laboratory will occur per 
instruc tions given to the study  site.
Bioanaly tical samples collected to measure for specified PD tests will be stored in a sponsor 
designated facilit yand retained for a maximum o f 5 years fo llowing the l ast pati ent visi t for the 
study .
CCI
I3Y-MC-JPBA (j)Phase 1 Oncology Protocol Amendment Page 50
LY28352197.2.3. Samples for Standard Laboratory Testing
Blood and serum samples (Attachment 2 )will be collected at the times specified in the Study  
Schedule ( Attachment 1 ).
Invest igato rs must docum ent thei r review o f each laboratory  safety  report .
Samples collected for specified laboratory tests will be destroyed within 60 days of receipt of 
confirmed test results.  Tests are run and confirmed prompt ly whenever medically or 
scientifical ly appropriate.  When medical and scient ific circumstances warrant, however, it is 
acceptable to retain samples to batch the tests run.  Certain samples may be retained for a longer 
period, if necessary, to comply wit h applicable laws, regulat ions, or l aboratory  certificat ion 
standards.
CCI
I3Y-MC-JPBA (j)Phase 1 Oncology Protocol Amendment Page 51
LY28352197.3. Efficacy Evaluations
A secondary  object ive of the study  is to docum ent any ant itumor activit y.  Ref er to Attachment 1
for details regarding the timing of specific efficacy measures.
Each patient will be assessed by  one or m ore of the fo llowing radi ologic tests for tum or 
measurement:
Com puteri zed tom ography  (CT) scan
Magnet ic resonance imaging (MRI) scan
Chest x -ray
Each patient’s full extent of disease will also be assessed with the fo llowing procedures:
Tumor measurement of pal pable or vi sible lesio ns (refer to RECIST 1.1) 
Evaluat ion of tumor markers, if indicated.
Evaluat ion of performance status (refer to the ECOG Scale, Attachm ent 6).
All lesion assessments, whether by physical exam or radiological methods, should be repeated by  
the sam e method at l east 4 weeks fo llowing the initi al observati on of  an object ive response to 
CCI
I3Y-MC-JPBA (j)Phase 1 Oncology Protocol Amendment Page 52
LY2835219ensure response confirmat ion.  If a patient is discont inued fro m the study , repeat radi ology may 
be omitted if there are clear clinical signs of progressive disease .  CT scans and MRIs may be 
requested to be sent to an off -sitestorage facilit y, and potential lyindependent lyreview ed and/or 
read by Lilly or i ts desi gnee .
7.4. Procedure/Sampling Compliance
Every  attem pt will be m ade to enroll patients who have the ability to understand and co mply 
with instructi ons.  Noncom pliant pati ents m ay be discontinued fro m the study .
The collection t imes of safet y assessments, PK samples , PD sam ples, and efficacy measurements 
are given as targets, to be achieved wit hin reasonable limits.  The scheduled time po ints may be 
subject to minor alterations; however, the actual collect ion time must be correctly recorded on 
the eCRF.
The scheduled collection times may be modified by the sponsor based upon analysis of the safet y 
and PK informat ion obtained during the study .  Any  major m odificat ions that might affect the 
conduct of the study , pati ent safet y, and/or data integrit y will be detailed in a protocol  
amendment.
I3Y-MC-JPBA (j)Phase 1 Oncology Protocol Amendment Page 53
LY28352198.Data Management Methods
8.1. Data Quality Assurance
To ensure accurate, complete, and reliable data, Lilly or its representatives will do the fo llowing:
provi de instructi onal materi al to the study  sites, as appropriate
sponsor start -up tra ining to instruct the invest igators and study  coordinators.  This sessio n 
will give instruction on the protocol, the completion of the CRFs, and study  procedures
make periodic visit s to the study  site
be available for consultation and stay  in contact with the study  site personnel by  mail, 
telephone, and/or fax
Review and evaluate eCRF data and/or use standard computer edits to detect 
errors in data collection.
Conduct a p eriodic review of the database.
In addit ion, Lilly or its representatives may perio dically check a sample of the patient data 
recorded against source documents at the study  site.  The study  may be audi ted by  Lilly and/or 
regul atory  agencies at any  time.
The invest igator will keep records of all original source data.  This might include l aboratory  
tests, m edical records, and clinical notes.  If requested, the invest igator will provide the sponsor, 
applicable regulatory  agencies, and applicable IRB/ERBs with direct access to the original 
source documents.
8.2. Data Capture S ystems
8.2.1. Case Report Form
An electronic data capture sy stem  will be used in this study .  The si te maintains a separate source 
for the data entered by  the si te into the sponsor -provided ,electroni c data capture system.
Any data for which paper documentation provided by the pati ent will serve as the source 
docum ent will be i dentified and documented by  each si te in that si te’s study  file.  Paper 
docum entati on provi ded by  the pat ient may include, for example, a paper diary  to collect pati ent-
reported outcome measures, a daily dos ing schedule or an event diary .
For data handled by a data management third party organi zation (TPO ), CRF data and some or 
all data that are related will be managed and stored electronically in the TPO system.  
Subsequent to the final database lock, validated data will be transferred to Lilly’s data 
warehouse, using standar d Lilly  file transfer processes .
For data handled by Lilly internally, CRF data and some or all data that are related will be 
managed by Lilly  and store d electronically in the Lilly’ s system .
I3Y-MC-JPBA (j)Phase 1 Oncology Protocol Amendment Page 54
LY28352198.2.2. Ancillary Data
Data m anaged by  a central  vendor will  be stored electronically  in the central  laboratory’s
database system.  Data will subsequent ly be transferred from the central vendor to the Lilly 
system  and TPO syste m.
Bioanaly tical data will  be stored electronically in the bioanaly tical laboratory ’s database.  Data 
will subsequently be transferred fro m the bioanaly tical laboratory  tothe Lilly system  and TPO 
system .
Electrocardiogram data will be stored electronicall y in the central database system o f Lilly’s 
central  review organi zation.  Data will subsequent ly be transferred from the central review 
organi zation system to the Lilly system and TPO system.
I3Y-MC-JPBA (j)Phase 1 Oncology Protocol Amendment Page 55
LY28352199.Data A nalyses
9.1. General Considerations
Patients willbe enrolled i n this mult icenter ,open -label ,Phase 1 study  with dose escalat ion  
 design followed by  dose confirmat ion in 6tumor-specific expansi ons.  During dose 
escalat ion, pati ents were enrolled  thetotal number of pat ients in a 
specific cohort wasdetermined based on the occurrence of DLTs at that dose l evel (refer to 
Secti on 6.2.2 ),   During dose confirmation, at least 
15and up to 45 -60 patients will be enro lled in each of 6 tumor-specific cohort expansio ns (refer 
to Section 6.2.3 ).
Statistical analysis o f this study  will be the responsibilit y ofEli Lilly and Company .
The analyses for this study  will be descript ive.  D ata analyses will be provided  
for all study  patients combined wherever appropriate.  For continuous variables, summary  
statist ics will include number of patients, mean, median, standard deviat ion, standard error, 
minimum, and maximum.  C ategori cal endpoints will  be summarized using number of patients, 
frequency , percentages, and their standard errors .  For time to event endpo ints, the Kaplan -Meier 
curves (Kaplan and Meier 1958) will be est imated .  Quartiles and rates at various time po ints, 
together with the 95% CIs, will be provided. Missing data will not be imputed.
The interpretation of the study  resul ts will be the responsibilit y of the invest igator with the Lilly
CRP, pharmacokineticist, statistician and Associate Consultant for Clinical Trial Management.  
The Lilly CRP and statist ician will also be responsible for the appropriate conduct of an internal 
review process for both the final study  report and any  study -related m aterial to be authori zed for 
publicat ion by Lilly.
 
9.1.1. Determination of Sample Size (Parts B, C, D, E, F ,and G )
Although at least 
patients will be enrolled in each of the 6 tumor-specific expansio ns, up to 
45-60 patients may be en rolled in each tumor -specific expansio n if approved by  the sponsor.  
The sample size of up to 45 -60 patients for each of the 6 tumor-specific expansio ns is based on  
different iating 34.5% to 40% from 5% (uninteresting) overall response rate (ORR) in tumors
with (marker present) and without (marker absent) a tumor -relevant exploratory  marker ,
respectively  (that i s, ORR marker present =34.5% to 40% and ORR marker absent =5%).  Exam ples of 
tumor-relevant exploratory markers include KRAS (non -small cell  lung cancer , colorectal  
cancer), CDKN2A (glio blastoma mult iforme, melano ma), and estrogen receptor (ER; breast 
cancer).  Assuming an equal number of pat ients having tumors with and wit hout the exploratory  
marker, 45 or 60 patients provide approximately 85% power to d ifferent iate 40% or 34.5% from 
5% ORR ,respectively (refer to Table JPBA .9.
1).To m aximize the power to detect the ORR 
difference between the marker groups, enrollment to a tumor- specific expansio n may be adjusted 
to achieve an equal number of patients having tumors with and wit hout the exploratory  marker.
CCI
CCI
CCI
CCI
CCI
CCI
I3Y-MC-JPBA (j)Phase 1 Oncology Protocol Amendment Page 56
LY28352199.1.2. Patient Disposition
All patients who discont inue from the study  will be identified, and the extent of their 
participat ion in the study will be reported.  If known, a reason for their discont inuat ion will be 
given.
9.1.3. Patient Characteristics
Patient characterist ics will include a summary o f the fo llowing:
Patient dem ographics
Baseline disease characterist ics
Prior disease -related therapi es
Concomitant medicat ions
Other patient characterist ics will be summarized as deemed appropriate.
9.1.4. Safety Analyses
Safety analyses will be conducted on all pat ients who have received at least 1 dose of the study  
drug.  
All p atients who receive at least 1 dose of LY2835219 will be evaluated for safet y and toxi city.  
Adverse events will be classified using the CTCAE 
Safety analyses will include summaries of the fo llowing:
AEs, including severit y and possible relationship to study  drug
Dose adjust ments
DLTs
Laboratory  measures and electrocardiograms .
9.1.5. Pharmacokinetic Analyses
Pharmacokinet ic(PK) analyses will be conducted on patien ts who have received at least 1 dose 
of the study  drug and have sufficient samples collected to allow the est imation of LY2835219 
PK parameters .
CCI
CCI
I3Y-MC-JPBA (j)Phase 1 Oncology Protocol Amendment Page 57
LY2835219Pharmacokine tic (PK) param eter estimates for LY283521 9 will be computed by standard 
nonco mpart mental methods of analysis using  Professional Edit ion on a com puter that 
meets or exceeds the minimum requirements for this program.  The maximum concentration 
(Cmax), area under the concentration -time curve (AUC), half -life(T1/2), volume of distribut ion 
(Vd), clearance (CL), and other relev ant parameters that can be calculated from t he data will be 
reported from the nonco mpartmental  analyses.
Provi ding that the data allow, the PK parameter estimates ( Cmaxand AUC) for LY2835219 will 
be evaluated statist ically to delineate the effects of dose proportionalit y using the methods 
described previously (Smit h et al . 2000). Least -squares estimates of geo metric m eans and their 
corresponding 90% confidence intervals (CI) will be provided by dose, together with the dose -
norm alized r atio of geom etric means and CI.
In addit ion, the plasma PKdata of LY2835219 will also be analyzed using nonlinear mixed 
effect modeling (Secti on 9.1.7 ).  The versio n of any so ftware used for the analysi s 
will be documented and the program will meet Lilly requirements of software validat ion.  It is 
possible that other validated equivalent PKsoftware programs may be utilized if appropriate, 
warranted, and approved by Lilly  Global PKmanagem ent.
Finally , in Part G , the plasma concentration data of fulvestrant will also be analyzed by standard 
nonco mpart mental methods of analysis , and any relevant PK parameter that can be calculated 
from the data will be reported.
9.1.7. Pharmacokinetic/Pharmacodynamic Analyses
In addit ion to a standard noncompartmental assessment, the plasma concentrati on data of 
LY2835219 willalso be analyzed by means o f a com partmental  approa ch using  
Plasma data fro m all pat ients will be pooled for analyses to determine the compart mental PK 
param eters and between -and wit hin-patientvariabilit y.Covari ates analysis will be also 
perform ed.Once a structural and statist icalmodel has been established, the effect of patient 
factors will be assessed. Covariate data distributions will be assessed.
This populat ion PK m odel will then be used to develop a PK/PD model where the levels o f Rb, 
pRb and topoIIα in hair fo llicles are the primary  PD measure. Addit ionalPK/PD m odels m ay be 
developed using other PD m easures.
Since a secondary  objective of this clinical tri al is to determine a recommended dose range of
LY2835219 that may be safely administered to patients with advanced cancer, the re sultsfrom 
these analyses maybe used to support dose selection for Phase 2 studies.
CCI
CCI
CCI
CCI
I3Y-MC-JPBA (j)Phase 1 Oncology Protocol Amendment Page 58
LY2835219ThePK/PD data will be analyzed using validated software programs (for example, 
). The versio n of the software used for the analysis will be documented and will 
meet the Lilly requirements of so ftware validat ion.
9.2. Efficacy
Response and progression for tumors will be evaluated using the Response Evaluat ion Cri teria in 
Solid Tumors (RECIST) Version 1.1 (Eisenhauer et al. 2009), with the notable ex ception that 
response and progression for lympho mas will be evaluated using the Revised Response Criteria 
for Malignant Lympho ma (Cheson et al. 2007).
Tumor response and time- to-event data will be tabulated.  For each expansio n cohort , the time -
to-event da ta analysis will include calculat ion of6-month progression -free survival probabilit y.  
Any pat ient that di scont inues due to a reason other than progressive disease or death (for 
example, AE, patient/invest igator decisio n) will have their t ime-to-event dat a either censored at 
Visit 801 if no progressive disease is found during this visit, or censored at the date of the last 
objective progression -free disease assessment if progressive disease is found at Visit 801.
For Part G, patients may have already  recei ved 1or more cy cles of fulvestrant pri or to study  
enrollment.  This prior therapy confounds the interpretation of response and progression.  As a 
resul t, tabul ations of tumor response and time- to-event data will be considered descriptive only.
9.3. Interim Ana lyses
Although an external safet y review co mmittee will not be formed, safet y data for all pat ients will 
be reviewed continuously  throughout thi s study  by Invest igators , the Lilly  CRP, and Lilly Glo bal 
Patient Safet y.
Only the assessment committee is autho rized to review com plete interim analyses.  Study  sites 
will receive inform ation about interim result s ONLY if they  need to know for the safet y of their 
patients or for dose escalat ion.  The assessment committee may consist of the members of the 
study  team .
9.3.1. Analysis by Cohort during Dose Escalation (Part A)
Safety and PK data will be transferred to Lilly  at the end of each com pleted cohort.  A summary 
of safet y and PK data will be provided.
9.3.2. Interim Analyses
Safety, PK, and PD data will be transferred to Lilly at the complet ion of d
ose escalat ion (Part A).
Safety, efficacy , PK, and PD data will be transferred to Lilly approximately  every 3 m onths 
and/orat the completion of each tumor -specific expansio n (Parts B, C, D, E, F,and G ).
CCI
CCI
I3Y-MC-JPBA (j)Phase 1 Oncology Protocol Amendment Page 59
LY283521910.Informed Consent, Ethical Review, and 
Regulatory Considerations
10.1. Informed Consent
The invest igator is responsible for ensuring that th e pati ent understands the potential risks and 
benefits of part icipating in the study, including answering any questions the patient may have 
throughout the study  and sharing in a timely manner any  new informat ion that m ay be rel evant to 
the pati ent’s willi ngness to continue his or her participat ion in the study  in a timely manner .
The informed consent document will be used to explain the potential risks and benefits of study 
participat ion to the patient in simple terms before the pat ient is entered into the study  and to 
docum ent that the pati ent is satisfied with his or her understanding of the potential risks and 
benefits of part icipating in the study and desires to participate in the study.
The invest igator is ult imately responsible for ensuring that infor med consent is given by each 
patient or l egal representati ve before the study  is started.  Thi s includes obtaining the appropriate 
signatures and dates on the informed consent document prior to the performance of any protocol 
procedures and prior to the ad ministration of study drug. 
In thi s protocol , the term  "informed consent" includes all consent and assent given by  patients or 
their legal representatives.
10.2. Ethical Review
Lilly must agree with all inform ed consent docum ents before they  are submitted to the IRB/ERB 
and are used at invest igative sites(s).  All informed consent documents must be compliant with 
the International Conference on Harmonisat ion guideline on Good Clinical Practice (GCP).  
Inform ed consent obtained unde r special  circumstances m ay occur only if allowed by  local laws 
and regulations, and performed in accordance wit h a wri tten process approved by  Lilly .
The invest igator will provide Lilly wit h documentation of IRB/ERB approval o f the protocol and 
the inform ed consent docum ent before the study  may  begin at the invest igative site(s).  Any 
member of the IRB/ERB who is direct ly affiliated with this study as an invest igator or as site 
personnel must abstain fro m the review board’s vote on the approval o f the prot ocol.  The 
IRB/ERB(s) will review the protocol as required.
The invest igator will supply the fo llowing to the investigative site’s IRB/ERB(s):
the current IB and updates during the course of the study
inform ed consent docum ent
relevant curri cula vi tae.
10.3. Regulatory Considerations
This study  will be conducted in accordance wit h:
I3Y-MC-JPBA (j)Phase 1 Oncology Protocol Amendment Page 60
LY28352191)Consensus ethics principles derived fro m internat ional ethics guidelines, including the 
Declaration of Helsinki and council for International Organizat ions of Medical 
Sciences (C IOMS) International Ethical Guidelines
2)The International Conference of Harmonisat ion(ICH) Good Clinical Pract ices 
(GCP) Guideline [E6]
3)Applicable laws and regulations
The investigator or designee will prompt ly submi t the protocol  to applicable ERB/IRB(s).
LY2835219 is being studied in the United States (US) under a US Invest igational New Drug 
(IND) applicat ion.  The US IND number is 106100.
Some of the obligat ions of the sponsor will be assigned to a contract research organizat ion 
(CRO).
An identificat ion code assigned by the invest igator to each patient will be used in lieu of the 
patient’s name to protect the patient’s ident ity when reporting AEs and/or other trial -related data.
10.3.1. Investigator Information
Site-specific contact informat ion may be provi ded in a separate document.
10.3.2. Protocol Signatures
After reading the protocol, each principal invest igator will sign the protocol signature page and 
send a copy  of the signed page to a Lilly representative.
10.3.3. Final Report Signature
The final report coordin ating invest igator or designee will sign the clinical study report for this 
study , indicat ing agreement that, to the best of his or her knowledge, the report accurately 
describes the conduct and results of the study .
The invest igator with the most enrolled pat ients will serve as the final report coordinat ing 
investigator.  If this investigator is unable to fulfill this function, another invest igator will be 
chosen by Lilly to serve as the final report coordinating invest igator.
The sponsor’s responsible med ical o fficer will sign the final clinical study  report for this study , 
confirming that, to the best of his or her knowledge, the report accurately describes the conduct 
and results of the study .
I3Y-MC-JPBA (j)Phase 1 Oncology Protocol Amendment Page 61
LY283521911.References
Cancer Therapy  Evaluat ion Program, Co mmo n Termino logy Criteria for Adverse Events, 
Versi on 4.0., NCI, NIH, DHHS. 200 9. Publish date:  29May 2009.
Cheson BD, Pfist ner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, 
Hagenbeek A, Zucca E, Rosen ST, Stroobants S, Lister TA, Hoppe RT, Dreyling M, Tobinai 
K, Vose JM, Connors JM, Federico M, Diehl V; International Harmonizat ion Project on 
Lympho ma. Revised response criteria for malignant lympho ma.  J Clin Oncol . 
2007;25(5):579 -
586.
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, 
Gwy ther S, Mooney  M, Rubinstein L, Shankar L, Dodd L, Kapla n R, Laco mbe D, Verweij J.
New response evaluat ion criteria in so lid tumours: revised RECIST guideline (versio n 1.1). 
Eur J Cance r. 2009; 45(2) :228-
247.
Hazra A, Krzyzanski W, Jusko WJ. Mathemat ical Assessment of Properties o f Precursor -
Dependent Indirect Pharmacodynamic Response Models. J Pharmacokinet Phamacodyn . 
2006; 33(6):683 -717.
Malumbres M.; Barbacid, M. To cy cle or not to cyc le: a crit ical decisio n in Cancer. Nat Rev 
Cancer . 2001;1: 222-
231.
Mager DE, Jusko WJ. Pharmacodynamic Modeling of Time -Dependent Transduct ion Systems.
Clin Pharm Ther . 2001;70(3):210 -216.
Oken MM, Creech RH , 
Torm ey DC, Horton J , Davis TE, McFadden ET, Car bone PP. Toxi city 
and response criteria of the eastern cooperative oncology  group .Am J Clin Oncol . 
1982;5:649 -655.
Ortega S, Malumbres M, Barbacid M. Cyclin -D dependent kinases INK4 inhibitors and Cancer. 
Biochim Biophys Acta. 2002;1602: 73-87.
Rizzo JD, Brouwers M, Hurley P, Seidenfeld J, Arcaso y MO, Spivak JL, Bennett CL, Bohlius J, 
Evanchuk D, Goode MJ, Jakubowski AA, Regan DH, Somerfield MR; American Societ y of 
Clinical Onco logy; American Societ y of Hematol ogy. American Societ y of Clinical  
Onco logy/Amer ican Soci ety of Hematol ogy clinical  practice gui deline update on the use of 
epoetin and darbepoetin in adult pat ients with cancer. J Clin Oncol .
2010;28(33):4996 -5010.
Sherr C J. Cancer Cell Cycle. Science . 1996; 274:1672-
1677.
Sharm a A, Ebling WF, Jusko WJ . Precursor -Dpendent Indirect Pharmacodynamic Response 
Model  for Tol erance and Rebound Phenomena. J Pharm Sci. 1998; 87(12):1577 -
1584.
Simeoni M, Magni P, Cammia C, De Nicolao G, Croci V, Pesent i E, Germ ani M, Poggesi  I, 
Rocchet i M. Predi ctive Pharmacokinet ic-Pharmacodynamic Modeling of Tumor Growth 
Kinet ics in Xenograft Models after Admin istrati on of  Anti cancer Agents. Cancer Res.
2004;64(3):1094 -1101.
Smith BP, Vandenhende FR, DeSante KA, Farid NA, Welch P A, Callaghan JT, Forgue ST. 
Confidence interval cri teria f or assessment of dose proportionalit y. Pharm Res.
2000; 17(10):1278 -1283.
I3Y-MC-JPBA (j)Phase 1 Oncology Protocol Amendment Page 62
LY2835219Smith TJ, Bohl ke K, Lyman GH, Carson KR, Crawford J, Cross SJ, Goldberg JM, 
Khatcheressian JL, Leighl NB, Perkins CL, Somlo  G, Wade JL , Wozniak AJ, Armitage JO; 
American Societ y of Clinical  Oncol ogy. Recommendat ions for the use of WBC growth 
factors: American Societ y of Clinical  Oncol ogy Clinical Practice Guideline Update. J Clin 
Oncol . 2015;33(28):3199- 3122.
Sun Y -N, Jusko WJ. Transit C ompartm ent versus Gamma Distribution Funct ion to Model Signal 
Transduct ion Processes in Pharmacodynamics. J Pharm Sci. 1998;87(6):732 -737.
I3Y-MC-JPBA (j)Phase 1 Oncology Protocol Amendment Page 63
LY2835219Attachment 1. Protocol JPBA
Study Schedule
I3Y-MC-JPBA (j)Phase 1 Oncology Protocol Amendment Page 64
LY2835219Schedule 1:   Assessment sfor Parts A , B, C , D,E, F,and G
Cycle/VisitPre-study /
Visit 0Cycle 1 Cycle 2 and 
BeyondFollow -
Upo
Relative Day Prior to Day 1 of Cycle 1-28 
to
-4-14
to 
-4-3* -2 -1 18
±215
±222
±228 291to 
2728
±2p
Informed Consent X
Medical History X X X X
Pregnancy Test (if applicable)Xa
Physical Exam X X X X X
Vital Signs and Weight  
(Temperature, Pulse Rate, Blood Pressure, Respiratory 
Rate)X X X X XX X
Height X
Chest X -rayb X Xh
Performance Status X X X X
CTCAE GradingXc X XX X d
Concomitant Medications X X X X
Tumo r Measurement (Palpable and Visible)X XX X
ECG e X X X X X
LY2835219 Therapy f X X X X X X X X
Fulvestrant Therapy ( Part G only) XqXrX X
Radiological Tumor Assessment g X Xh
Archived Tumor S amples i X
Tumo r Biopsy Xj Xj
Hematology k X X X X X X X X
Serum Chemistry k X X X X X X X X
Serum Cortisol (random) X X X
Lymphocy te Subset Analysis
(CD3, 4, 8, and 19)X X X
CCI
I3Y-MC-JPBA (j)Phase 1 Oncology Protocol Amendment Page 65
LY2835219Study Schedule 1:  A ssessments for Parts A , B, C , D,E, F,and G (Continued )
Cycle/VisitPre-study /
Visit 0Cycle 1 Cycle 2 and 
BeyondFollow -
Upo
Relative Day Prior to Day 1 of Cycle 1-28 
to
-4-14
to 
-4-3* -2 -1 18
±215
±222
±228 291
to 
2728
±2p
Blood PK Sampling l X X X X X X X X
CSF PK Sampling l,m X X
Hair F ollicle (PD sample) l X X X X
Skin B iopsy (PD sample) l Xc X
DNA Genotyping Blood Sample (stored) Xc
Record results for any tumor markers in 
clinical database, if applicableX X X
Abbreviations:  CSF = cerebrospinal fluid; CTCAE = Common Terminology Criteria for Adverse Events ;ECG = electrocardi ogram; PK =pharmacokinetic; 
PD= pharmacodynamic .
*= Day -3 in Cycle 1 has to be either on Monday or Tuesday only.
aFemales with child be aring potential must have a negative serum pregnancy test within 3 days of the first dose of study drug ( i.e., Day -6 to Day -4).
bChest X -ray may be omitted in patients having a chest CT as part of their radiological tumor assessment.   Radiological tumor assessment, including Chest 
X-ray ,is performed at baseline (Day -28 to Day -4), then between Day 21 and Day 28 of every  other cycle beginning with Cycle 2.
cObtain o nly after study  eligibility  is confirmed.
dAll drug- or procedure -related adverse events and serious adverse events should be followed until the y resolve, are no longer considered to be drug -or 
procedure -related, become stable or return to baseline, the patient starts a new therapy, the patient dies ,or the patient becomes lost to follow -up. Frequency of
evaluation is left to the judgment of the investigator.
eA central E CGs (no replicates required) should be obtained at baseline (Day -14 to Day -4) and at the following time points during Cycle 1 only:  pre-dose, 2 
and 4 hrs post -dose on Day -3; both Day -2 and Day -1 (as close to PK sample collection as possible); predose, 2 and 4 hrs postdose on Day 15.
fFor the once daily schedule , LY2835219 is to be administered ever y 24 hours on Days 1 through 28 of each cycle except in Cycle 1, when study d rug will be 
administered as a single (morning) dose on Day -3 and then ever y 24 hours on Days 1 to 27.  For the 
twice daily schedule , LY2835219 is to be administered 
every 12 hours on Days 1 through 28 of each cycle except in Cycle 1, when LY2835219 will be administered as a single (morning) dose on Day -3, every 
12 hours on Days 1 to 2 7, and as a single (morning) dose on Day 28.  Patients should not consume food beginning 1 hour before and ending 1 hour after 
taking study drug .
I3Y-MC-JPBA (j)Phase 1 Oncology Protocol Amendment Page 66
LY2835219Study Schedule 1:  A ssessments for Parts A , B, C , D,E, F, and G (Concluded )
gImaging studies areperformed locally .  Radiological tumor assessment is performed at baseline (Day -28 to Day -4), then between Day 21 and Day 28 
(inclusive) of every other cycle beginning with Cycle 2 ; if necessar y, radiological tumor assessment between Day 21 and Day 28 may be extended to Day 29 
or Day  30 if the Day  28 procedures occur on Day 29 or Day 30, respectively (refer to footnote p for additional information) . For patients with glioblastoma 
multiforme who are receiving corticosteroids (for example , dexamethasone), the baseline imaging study should be performed on a stable dose of 
corticosteroids.   For  patients with glioblastoma multiforme or brain metastases, radiol ogical tumor assessment should also include MRI scan (preferred) or CT 
scan of the brain.
hIf a patient is discontinued from the study, repeat radiology may be omitted if progressive disease can be documented quantitatively with clinical 
measurements .
iRequest archived paraffin -embedded tumor tissue (to be used for assessment of tumor Rb and p -Rb status ), but only after s tudy eligibility  is confirmed.
jOnly for patients in Parts B, C, D, E, F,and G .  Pre-treatment b iopsy should be obtained (whenever cl inically  feasible )between Day -14 and Day  -4,but only 
after study eligibility is confirmed.   Posttreatment biopsy should be obtained (whenever clinically feasible) between Day 8 and Day 22.  Greater flexibility has 
been provided for the post -treatment tu mor biopsy  (157) compared to other Day 15 assessments (15 2) to enable radiographic guidance and access to 
appropriate medical specialists.
kFor c entral versus local labs, refer to Attachment 2 .
oFollow -up starts just after the last dose of study drug and ends when final sa fety assessments are completed ( 30 ±7 days after last dose of study  drug ).
pIf Day  28 procedures occur on Day 29 or 30, then these procedures are included in the current cycle and initiation of the nex t cycle is delayed until the 
following da y.
qFor patients already receiving fulvestrant at time of study entry, ful
vestrant dose on Cycle 1 Day 1 should correspond approximately to the date of its expected 
monthly administration.
rFor patients already receiving fulvestrant at time of study entry, fulvestrant should not be administered on Cycle 1 Day 15 .
CCI
I3Y-MC-JPBA (j)Phase 1 Oncology Protocol Amendment Page 67
LY2835219Continued A ccess Assessments
Abbreviations:  AE = adverse event; CRF = case report form; CTCAE = Common Terminology Criteria for Adverse Event; SAE = serious adverse event.
Note:  Efficacy and laboratory assessments will be done at the investigator’s discretion based on the standard o f care.Cycle/Visit Cycles 501 -
5XXContinued Access 
Follow -up(901)Comments
Relative Day Within Cycle 1to 
2728
±2
Adverse Events Collection/CTCAE 
GradingX XAll AEs and SAEs will be reported on the CRF.
LY2835219 Therapy X X LY2835219 is to be administered according to Section 6.2.1 .  
Study drug exposure will be reported on the CRF.
Fulvestrant Therapy ( Part G only) XFulvestrant (Part G) is to be administered according to 
Section 6.2.1 . Study drug exposure will be reported on the 
CRF.
I3Y-MC-JPBA (j)Phase 1 Oncology Protocol Amendment Page 68
LY2835219Attachment 2. Protocol JPBA
Clinical Laboratory  Tests
Clinical Laboratory Tests
Hematology a Clinical Chemistry a(except as indicated)
Hemoglobin Serum Concentrations of:
Hematocrit Sodium
Erythrocy te count (RBC) Potassium
Mean cell volume (MCV) Bicarbonate b(local only)
Mean cell hemoglobin concentration (MCHC) Chloride
Leukocytes (WBC) Glucose (random)
Neutrophils (segmented + bands)
Lymphocy tes Calcium
Monocytes Albumin
Eosinophils Total Protein
Basophils Blood Urea Nitrogen (BUN)
Platelets Creatinine
Reticulocyte count a(central only) Alkaline Phosphatase
Alanine A minotransferase (ALT)
Aspartate A minotransferase (AST)
Total Bilirubin and Direct Bilirubin
Creatine K inase (CK) Total
Lactate D ehydrogenase (LDH)
Uric Acid
Serum Pregnancy T est(females only) b(local only)
Special Blood Tests a(central only)
Serum Cortisol (random)
Lymphocy te Subset Analysis (CD3, 4, 8, and 19)
Abbreviations :  RBC = red blood cells;WBC = white blood cells;INR = International Normalized Ratio.
aAssay ed by Lilly -designated (central) laboratory .
bAssay ed by investigator-designated (local) laboratory .
I3Y-MC-JPBA (j)Phase 1 Oncology Protocol Amendment Page 69
LY2835219Attachment 3. Protocol JPBA
Recommended Hepatic Monitoring Tests for Treatment 
Emergent A bnormality
Hepati c Hematology a Haptoglobin a
Hemoglobin
Hematocrit Hepatic Coagulation a
RBC Prothrombin Time
WBC Prothrombin Time, INR
Neutrophils, segmented
Lymphocy tes Hepatic Serologies a,b
Monocytes Hepatitis A antibody, total
Eosinophils Hepatitis A antibody, IgM
Basophils Hepatitis B surface antigen
Platelets Hepatitis B surface antibody
Hepatitis B Core antibody
Hepatic Chemistry a Hepatitis C antibody
Total bilirubin Hepatitis E antibody, IgG
Direct bilirubin Hepatitis E antibody, IgM
Alkaline phosphatase
ALT Anti -nuclear antibody a
AST
GGT Anti -smooth muscle antibody a
CPK 
Abbreviations:  ALT = alanine aminotransferase; AST = aspartate aminotransferase; CPK = creatine phosphokinase; 
GGT = gamma glutamyl transferase; Ig = immunoglobulin; INR = International Normalised Ratio; RBC = red 
blood cells; WBC = white blood cells.
aAssay ed by local laboratory.
bReflex/confirmation dependent on regulatory requirements and/or testing availability .
I3Y-MC-JPBA (j)Phase 1 Oncology Protocol Amendment Page 70
LY2835219Attachment 4.Protocol JPBA
Pharmacokinetic and Pharmacody namic Sampling Schedule
PK Sample 
NumberDay in Cycle 1LY
2835219 DosingSampling Time for PK from 
blood
(LY2835219) aSampling Time for PK from 
CSF
(LY2835219) a
(Parts B, C, D , E, Fonly)
-14 to -4
1 -3 X Pre-dose (0 h) Pre-dose (0 h) d
2 -3 1 h± 10 min post-dose
3 -3 2 h± 10 min post-dose
4 -3 4h± 20 min post-dose
5 -3 6 h ± 20 min post-dose
6 -3 8 h ± 20 min post-dose
7 -3 10 h ± 20 min post -dose e
8 -2 No dose 24 ± 2 h post -dose
9 -1 No dose 48 ± 2 h post -dose
10 1 X Pre-dose
11 15 X Pre-dose (0 h)
12 15 1 h± 10 min post-dose
13 15 2 h± 10 min post-dose
14 15 4 h ± 20 min post-dose 4 h post -dosed
15 22 X Pre-dose (0 h)
16 28 X Pre-dose (0 h)
17 28 1 h ± 10 min post-dose
18 28 2 h ± 10 min post-dose
19 28 4 h ± 20 min post-dose
20 28 6 h± 20 min post-dose
21 28 8 h ± 20 min post-dose
22 28 10 h ± 20 min post -dose e
23 29 Nodose 24± 2h post -dose
CCI
I3Y-MC-JPBA (j)Phase 1 Oncology Protocol Amendment Page 71
LY2835219Pharmacokinetic and Pharmacodynamic Sampling Schedule (Concluded )
Abbreviations: CSF = cerebrospinal fluid; h or hrs = hours ;min = minutes ;PD = pharmacodynamic ;PK = pharmacokinetic.
aSamples of approximately 2 mL of whole blood will be drawn to measure concentrations of fulvestrant (Part G only), LY2835219 , and its metabolites .  
concentrations .For Part G, the pre -dose PK samples on Days 1, 15, 22, and 28 will also be used to measure concentrations of fulvestrant.  Samples of 
approximately 2 mL of cerebrospinal fluid will be drawn for measurement of LY2835219 and its metabolites.  If a patient does not take the LY2835219 dose 
on a day with PK sampling, then it does not constitute a protocol violation to omit collection of the “post -dose” PK samples for that day.
For dose confirmation (Parts B, C, D, E, F and G) only, patients with glioblastoma multiforme or brain metastases should have lumbar puncture at these time
points (whenever clinically feasible) with collection of approximately 2ml of cerebrospinal fluid for measurement of LY2835219 .  To provide flexibi lity for 
patients and study personnel, the baseline (pre -dose) sample on Day -3 may  be obtained before the first dose of study drug from Day -14 through Day -3; the 
sample (4 h post -
dose) on Day 15, though preferably obtained at approximately the same time as a corresponding plasma PK sample, may be o btained 2 to 8 
hourspost-dose.  In no instance should the timing of other PD or blood PK samples be compromised due to constraints associated with col lection of the CSF 
sample.   Omission of CSF samples (for ex ample , not clinically feasible) will not constitute a protocol violation.
eIf patient constraints preclude collection of this 10 -hour PK sample, omission of this sample will not constitute a protocol violation.
CCI
I3Y-MC-JPBA (j)Phase 1 Oncology Protocol Am endment Page 72
LY2835219Attachment 5.Protocol JPBA
Recommendations for Reporting Serious Adverse Events
Recommendations for Reporting Serious Adverse Events
When tel ephoning the Lilly office to report a serious adverse event, please have the following 
inform ation available:
Patient Demographics
patient identificat ion (number)
sex
date of birth
race
height & weight
Study Identification
full trial protocol number
investigator's name
investigator’s number
Study Drug
drug code or drug name
unit dose
total daily dose
frequency
route
start dose
cycle details
start date & last dose date (if applicable)
(continued)
I3Y-MC-JPBA (j)Phase 1 Oncology Protocol Am endment Page 73
LY2835219Adverse Event
descript ion
date of onset
severit y
treatm ent (including hospitalizat ion)
action taken wi th respect to study  drug
clinical significance
test & procedure results (if applicable)
Relationship to Study Drug & Protocol Procedures
Concomitant Drug Therapy
indicat ion
total daily dose
durati on of  treatm ent
start date
action taken
In Case of Death
cause
autopsy  finding (if a vailable)
date
relationship to study  drug & protocol  procedures.
I3Y-MC-JPBA (j)Phase 1 Oncology Protocol Am endment Page 74
LY2835219Attachment 6.Protocol JPBA
ECOG Performance Status
Eastern Cooperative Oncology Group (ECOG) Performance Status
Activity Status Description
0 Fully  active, able to carry on all pre -disease performance without restriction.
1 Restricted in physically strenuous activity but ambulatory and able to carry out 
work of a light or sedentary nature (for example, light housework, office work).
2 Ambulatory and capable of all self -care but unable to c arry out any  work activities.  
Up and about more than 50% of waking hours.
3 Capable of only limited self -care, confined to bed or chair more than 50% of 
waking hours.
4 Completely disabled.  Cannot carry on any self -care.  Totally confined to bed or 
chair.
5 Dead.
Source:  Oken et al. 1982.
I3Y-MC-JPBA (j)Phase 1 Oncology Protocol Am endment Page 75
LY2835219Attachment 7.Protocol JPBA
Staging and Grading of A cute Graft -versus -Host Disease
Table 1. Criteria for Organ Staging
Stage Skin Liver Intestine
1 Rash o n <25% of skin Bilirubin ≥2 and <3 mg/dL Diarrhea >500 ml/day
2 Rash o n 25% -50% of skin Bilirubin ≥3 and <6 mg/dL Diarrhea >1000 ml/day
3 Rash o n >50% of skin or 
generalized erythrodermaBilirubin ≥6 and <15 mg/dL Diarrhea >1500 ml/day
4 Generalized erythroderma with 
bullous formationBilirubin ≥15 mg/dL Severe abdominal pain with 
or without ileus
Table 2. Overall Clinical Grading
Grade Skin Liver Intestine
I 1 0 0
I 2 0 0
II 0-2 0-1 1
II 0-2 1 0-1
II 3 0-1 1
II 3 1 0-1
II 3 0 0
III 0-2 0-2 2
III 0-2 2 0-2
III 0-3 2-3 0-3
III 3 0-3 2-3
III 0-3 4 0-3
IV 0-3 0-4 4
IV 4 0-4 0-4
References
Cahn J -Y, Kl ein JP, Lee SJ, Milpied N, Blaise D, Ant in JH, Leblo nd V, Ifrah N, Jouet J -P, 
Loberi za F, Ringden O, Barrett AJ, Horowitz MM, Socie G. 2005. Prospective evaluat ion of 2 
acute graft -versus -host (GVHD) grading systems:  a joint Societe Francaise de Greffe de 
Moelle et Therapie Cellulaire (SFGM -TC), Dana Farber Cancer Inst itute (DFCI), and 
International Bone Marrow Transplant Registry  (IBMTR) prospective study . Blood
106(4):1495 -1500.
Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA, Lerner KG, Thomas ED. 
1974. Clinical manifestations of graft -versus -host di sease in human recipients of marrow from 
HLA -matched sibling donors . Transplantation 18:295 -304.
I3Y-MC-JPBA (j)Phase 1 Oncology Protocol Am endment Page 76
LY2835219Przepi orka D, Weisdorf D, Martin P, Klingemann H- G, Beatty  P, Hows J, Thom as ED. 1995. 
Consensus conference on acute GVHD grading. Bone Marrow  Transplantation 15:825 -828.
Thomas ED, Strob R, Clift RA, Fefer A, Johnson FL, Neiman PE, Lerner KG, Glucksberg H, 
Buckner CD. 1975. Bone -marrow transplantation.  New England Journal of Medicine
292:895-902.
I3Y-MC-JPBA (j)Phase 1 Oncology Protocol Am endment Page 77
LY2835219Attachment 8.Protocol JPBA
Inducers and Strong Inhibitors of CYP3A
The informat ion in this Attachment is provi ded for gui dance to invest igators and does not 
precl ude the use of these medicat ions if clinically indicated.
Strong Inducers of CYP3A
Carbamazepine 
Dexamethasone *
Phenobarbital/phenobarbitone 
Phenytoin 
Rifapentine
Rifampin 
Rifabutin
St. Jo hn’s wort
Moderate Inducers of CYP3A
Bosentan
Lesinurad
Modafinil
Primidone
Telotristat ethyl
Strong Inhibitors of CYP3A
Aprepitant
Ciprofloxacin
Clarithromycin
Conivaptan
Diltiazem
Erythromycin
Fluconazole
Itraconazole 
Ketoconazole 
Nefazodone
Posaconazole
Troleandomycin
Verapamil
*Important note:  Patients with glioblastoma multi forme or brain metastases may receive acute or chronic therapy 
with dexamethasone ,if clinically indicated.  All patients may receive supportive therapy with dexamethasone , 
preferably 7 day s, if clinically  indicated .
I3Y-MC-JPBA (j)Phase 1 Oncology Protocol Am endment Page 78
LY2835219Attachment 9.Protocol JPBA
Protocol A mendment I3Y -MC-JPBA (j) Summary  
Phase 1 Study  of a CDK4/6 Dual Inhibitor in Patients with 
Advanced Cance r
Overview
Protocol  I3Y-MC-JPBA , aPhase 1 Study  of a CDK4/6 Dual Inhibitor in Pat ients with Advanced 
Cancer has been amended.   The new protocol is indicated by amendme nt (j)and will be used to 
conduct the study  in place of any  preceding versio n of the protocol.
Modificat ions to the study  protocol  introduced in amendment ( j) invo lve the fo llowing:
The Rat ionale for Amendment ( j) was added as Secti on 4.4.
Table JPB A.
6.2 was up dated with dose adjustment criteria for nonhematologic toxicit y
andALT/AST increased.
Inform ation formodulators of CYP3A and transporter substrates was updated in the 
section for Concomitant Therapy  (Secti on 6.5).
The Hepatic Moni toring guidance in Sect ion 7.1.3.1 wasupdated based on current 
inform ation
.
The safet y monitoring language for VTEs in Section 7.1.3.3 was updated.
Secti on 7.1.3.4 was edited slightly for clarit y to include specific ILD/pneumo nitis Grades 
requi ring LY2835219 discont inuat ion.
Minor ty pographical and form atting edi ts were made throughout the document for clarit y and 
consistency
Leo Document ID = 6da9678e-c557-4307-8091-269b1c14a618
Approver:
Approval Date & Time: 26-Feb-2021 01:55:10 GMT
Signature meaning: Approved
Approver:
Approval Date & Time: 26-Feb-2021 13:50:11 GMT
Signature meaning: Approved
PPD
PPD